CLDF Title
Home | Contact Us | Bookmark
  HBV   HCC   HCV   HE   NASH   PBC   THROMBOCYTOPENIA
About CLDF
Board of Trustees Board of Advisors/Faculty 2018 GI Fellow Board of Advisors
Centers of Educational Expertise  
Live CME Meetings Webcasts Slide Library Abstract Library Committee Members Conference Highlights
 
NASH Disease Content  
Live CME Meetings

NAS/NAFLD Disease state and trial awareness

The NASH/NAFLD Disease State and Trial Awareness meeting series will focus on advancing NASH/NAFLD and therapeutics knowledge by establishing a platform and forum for health care professionals to experience high-quality education delivered by leading experts in the field.

Recorded Educational Webinar



NASH Trial Opportunity

Find a NASH Clinical Investigator

Audiocasts from the Symposia at UEGW 2016 - Vienna, Austria
Webcast Library
     
Clinical Updates in the Management of Fatty Liver Disease in Patients with Type 2 Diabetes   Educational Webinar
Fatty Liver Disease in Adolescent and Pediatric Patients   Educational Webinar
AASLD 2018 Practice Guidance for Diagnosis and Management of NAFLD   Educational Webcast
A NASH Trial Opportunity for Your Overweight Metabolic Syndrome Patients   NASH Trial Opportunity
Current Approaches to Identifying and Managing Patients with NASH and What to Expect in the Future   CME Webcast
The Evolving Role of Invasive and Non-Invasive Assessment Tools in Liver Disease   Educational Webinar
Utility of VCTE (Fibroscan®) as A Prescreen Tool for NAFLD Clinical Trials   Educational Webcast
Utility of VCTE (Fibroscan®) in the diagnosis of NAFLD/NASH   Educational Webcast
2016 Expert Perspectives on NAFLD/NASH   Educational Webcast
NASH: Disease state and diagnosis   Educational Webcast
NASH: Diagnostic tools: biomarkers and imaging   Educational Webcast
NASH: Treatment update and the multidisciplinary approach from the hepatologist's perspective   Educational Webcast
NASH: Treatment update and the multidisciplinary approach from the endocrinologist's perspective   Educational Webcast
Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies   Audiocast
Best of the Liver Summit: PBC, NAFLD/NASH and HCV   CME Webcast
Hepatology Update: New Developments in PBC, NAFLD and NASH   Educational Webcast
Liver Summit   CME Webcast
 
 
Abstract Library
  1. The Triumph of Bacchus: The Emergence of Nonalcoholic Steatohepatitis and Alcoholic Liver Disease as the Leading Causes of Mortality from Cirrhosis
    Cotter TG1, Charlton M1. Hepatology. 2018 Dec 20. doi: 10.1002/hep.30408. [Epub ahead of print]


  2. Association of Parity in Patients with Chronic Liver Disease
    Golabi P1, Fazel S1, Otgonsuren M1, Escheik C1, Sayiner M1, Younossi ZM1. Ann Hepatol. 2018 Oct 16;17(6):1035-1041. doi: 10.5604/01.3001.0012.7204.


  3. Aetiology and severity of liver disease in HIV positive patients with suspected NAFLD: lessons from a cohort with available liver biopsies
    Prat LI1,2, Roccarina D1, Lever R3, Lombardi R1, Rodger A3,4, Hall A1,5, Luong TV1, Bhagani S3, Tsochatzis E1. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001942. [Epub ahead of print]


  4. Diagnostic accuracy of noninvasive markers of steatosis, NASH and liver fibrosis in HIV-monoinfected individuals at-risk of non-alcoholic fatty liver disease (NAFLD): results from the ECHAM study
    Lemoine M1, Assoumou L2, De Wit S3, Girard PM4, Valantin MA5, Katlama C5, Necsoi C3, Campa P4, Huefner AD6, Schulze Zur Wiesch J6, Rougier H4, Bastard JP7,8, Stocker H9, Mauss S10, Serfaty L11, Ratziu V12, Menu Y13, Schlue J14, Behrens G15, Bedossa P16, Capeau J8, Ingiliz P17, Costagliola D2. J Acquir Immune Defic Syndr. 2018 Dec 12. doi: 10.1097/QAI.0000000000001936. [Epub ahead of print]


  5. Prevalence of Nonalcoholic Fatty Liver Disease in Children with Obesity
    Yu EL1, Golshan S2, Harlow KE1, Angeles JE3, Durelle J3, Goyal NP1, Newton KP1, Sawh MC1, Hooker J4, Sy EZ4, Middleton MS4, Sirlin CB4, Schwimmer JB5. J Pediatr. 2018 Dec 14. pii: S0022-3476(18)31609-3. doi: 10.1016/j.jpeds.2018.11.021. [Epub ahead of print]


  6. Prior Bariatric Surgery in Liver Transplant Candidates: Unforeseen Consequences?
    Sharpton SR1, Terrault NA1. Liver Transpl. 2018 Dec 26. doi: 10.1002/lt.25401. [Epub ahead of print]


  7. Hepatic mast cell concentration directly correlates to stage of fibrosis in NASH
    Lombardo J1, Broadwater D2, Collins R2, Cebe K2, Brady R2, Harrison S3. Hum Pathol. 2018 Dec 28. pii: S0046-8177(18)30484-2. doi: 10.1016/j.humpath.2018.11.029. [Epub ahead of print]


  8. Increasing Incidence of Nonalcoholic Steatohepatitis as an Indication for Liver Transplantation in Australia and New Zealand
    Calzadilla-Bertot L1, Jeffrey GP1,2, Jacques B2, McCaughan G3, Crawford M3, Angus P4, Jones R4, Gane E5, Munn S5, Macdonald G6, Fawcett J6, Wigg A7, Chen J7, Fink M8, Adams LA1,2. Liver Transpl. 2019 Jan;25(1):25-34. doi: 10.1002/lt.25361.


  9. Consumption of decaffeinated coffee protects against the development of early non-alcoholic steatohepatitis: Role of intestinal barrier function
    Brandt A1, Nier A1, Jin CJ2, Baumann A1, Jung F1, Ribas V3, García-Ruiz C4, Fernández-Checa JC4, Bergheim I5. Redox Biol. 2018 Dec 23;21:101092. doi: 10.1016/j.redox.2018.101092. [Epub ahead of print]


  10. Universal Index for Cirrhosis (UIC index): The development and validation of a novel index to predict advanced liver disease
    Ahmed Z1, Ren J2, Gonzalez A3, Ahmed U4, Walayat S4, Martin DK5, Moole H4, Yong S6, Koppe S7, Dhillon S5. Hepat Med. 2018 Oct 24;10:133-138. doi: 10.2147/HMER.S160616. eCollection 2018.


  11. Pediatric Fatty Liver and Obesity: Not Always Justa Matter of Non-Alcoholic Fatty Liver Disease
    Alfani R1,2, Vassallo E3,4, De Anseris AG5, Nazzaro L6, D'Acunzo I7,8, Porfito C9,10, Mandato C11, Vajro P12,13,14,15. Children (Basel). 2018 Dec 13;5(12). pii: E169. doi: 10.3390/children5120169.


  12. Omega-3 fatty acids and nonalcoholic fatty liver disease in adults and children: where do we stand?
    Spooner MH1, Jump DB. Curr Opin Clin Nutr Metab Care. 2018 Dec 28. doi: 10.1097/MCO.0000000000000539. [Epub ahead of print]


  13. New insights into genetic predisposition and novel therapeutic targets for nonalcoholic fattyliver disease
    Barbara M1, Scott A2, Alkhouri N1,2.


  14. Prevalence and Outcomes of Non-alcoholic Fatty Liver Disease (NAFLD) among Asian American Adults in the United States
    Golabi P1, Paik J1, Hwang JP2, Wang S3, Lee HM4, Younossi ZM1,5. Liver Int. 2018 Dec 29. doi: 10.1111/liv.14038. [Epub ahead of print]


  15. Atrial fibrillation is highly prevalent yet undertreated in patients with biopsy-proven nonalcoholic steatohepatitis
    Whitsett M1, Wilcox J2, Yang A3, Zhao L3, Rinella M4, VanWagner LB3,4. Liver Int. 2018 Dec 7. doi: 10.1111/liv.14018. [Epub ahead of print]


  16. Gathering momentum for the way ahead: fifth report of the Lancet Standing Commission on Liver Disease in the UK
    Williams R1, Alexander G2, Aspinall R3, Batterham R4, Bhala N5, Bosanquet N6, Severi K7, Burton A8, Burton R9, Cramp ME10, Day N11, Dhawan A12, Dillon J13, Drummond C14, Dyson J15, Ferguson J16, Foster GR17, Gilmore I18, Greenberg J19, Henn C9, Hudson M15, Jarvis H20, Kelly D21, Mann J22, McDougall N23, McKee M24, Moriarty K25, Morling J26, Newsome P27, O'Grady J12, Rolfe L9, Rice P28, Rutter H29, Sheron N30, Thorburn D31, Verne J9, Vohra J32, Wass J33, Yeoman A34. Lancet. 2018 Dec 1;392(10162):2398-2412. doi: 10.1016/S0140-6736(18)32561-3. Epub 2018 Nov 22.


  17. Nonalcoholic-Fatty-Liver-Disease and Nonalcoholic Steatohepatitis: Successful Development of Pharmacological Treatment Will Depend on Translational Research
    Gottlieb A, Mosthael W, Sowa JP, Canbay A. Digestion. 2018 Dec 7:1-7. doi: 10.1159/000493259. [Epub ahead of print]


  18. Macrophages in the Aging Liver and Age-Related Liver Disease
    Stahl EC1, Haschak MJ1, Popovic B1, Brown BN1. Front Immunol. 2018 Nov 30;9:2795. doi: 10.3389/fimmu.2018.02795. eCollection 2018.


  19. Modulation of Insulin Resistance in NAFLD
    Khan R1,2,3, Bril F4,5, Cusi K4,5, Newsome PN1,2,3. Hepatology. 2018 Dec 16. doi: 10.1002/hep.30429. [Epub ahead of print]


  20. A Pathophysiologic Approach Combining Genetics and Insulin Resistance to Predict the Severity of Nonalcoholic Fatty Liver Disease
    Danford CJ1, Connelly MA2, Shalaurova I2, Kim M3, Herman MA4, Nasser I5, Otvos JD2, Afdhal NH1, Jiang ZG1, Lai M1. Hepatol Commun. 2018 Nov 1;2(12):1467-1478. doi: 10.1002/hep4.1267. eCollection 2018 Dec.


  21. Vitamin E Improves Transplant-free Survival and Hepatic Decompensation among Patients with NASH and Advanced Fibrosis
    Vilar-Gomez E1, Vuppalanchi R1, Gawrieh S1, Ghabril M1, Saxena R2, Cummings OW2, Chalasani N1. Hepatology. 2018 Dec 1. doi: 10.1002/hep.30368. [Epub ahead of print]


  22. Understanding Patient Preferences and Unmet Needs in Non-alcoholic Steatohepatitis (NASH): Insights from a Qualitative Online Bulletin Board Study
    Cook NS1, Nagar SH2, Jain A2, Balp MM3, Mayländer M4, Weiss O4, Chatterjee S2. Adv Ther. 2018 Dec 13. doi: 10.1007/s12325-018-0856-0. [Epub ahead of print]


  23. Improvements in Histologic Features and Diagnosis associated with Improvement in Fibrosis in NASH: Results from the NASH Clinical Research Network Treatment Trials
    Brunt EM1, Kleiner DE2, Wilson LA3, Sanyal AJ4, BA5; Neuschwander-Tetri Hepatology. NASH CRN. 2018 Dec 14. doi:10.1002/hep.30418. [Epub ahead of print]


  24. Non-alcoholic fatty liver disease in pediatric type 2 diabetes: Metabolic and histologic characteristics in 38 subjects
    Newfield RS1, Graves CL1, Newbury RO2, Schwimmer JB3, Proudfoot JA4, Say DS5, Feldstein AE3. Pediatr Diabetes. 2018 Nov 22. doi: 10.1111/pedi.12798. [Epub ahead of print]


  25. Lean non-alcoholic fatty liver disease
    Wang AY1, Dhaliwal J2, Mouzaki M3. Clin Nutr. 2018 Aug 17. pii: S0261-5614(18)31350-5. doi: 10.1016/j.clnu.2018.08.008. [Epub ahead of print]


  26. Liver Fat is Associated With Markers of Inflammation and Oxidative Stress in Analysis of Data From the Framingham Heart Study
    Fricker ZP1, Pedley A2, Massaro JM3, Vasan RS4, Hoffmann U5, Benjamin EJ6, Long MT7. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31280-1. doi: 10.1016/j.cgh.2018.11.037. [Epub ahead of print]


  27. Care of Patients Following Cure of Hepatitis C Virus Infection
    Terrault NA1. Gastroenterol Hepatol (N Y). 2018 Nov;14(11):629-634.


  28. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients with Non-alcoholic and Alcohol-Related Fatty Liver Disease
    Younossi ZM1, Stepanova M2, Ong J3, Yilmaz Y4, Duseja A5, Eguchi Y6, El Kassas M7, Castellanos-Fernandez M8, George J9, Jacobson IM10, Bugianesi E11, Wai-Sun Wong V12, Arrese M13, de Ledinghen V14, Romero-Gomez M15, Mendez-Sanchez N16, Ahmed A17, Wong R18, Papatheodoridis G19, Serfaty L20, Younossi I2, Nader F2, Ziayee M2, Afendy A2; Global NASH Council. Clin Gastroenterol Hepatol. 2018 Nov 23. pii: S1542-3565(18)31276-X. doi: 10.1016/j.cgh.2018.11.033. [Epub ahead of print]


  29. Non-Alcoholic Fatty Liver Disease-A Global Public Health Perspective
    Younossi ZM1. J Hepatol. 2018 Nov 8. pii: S0168-8278(18)32517-0. doi: 10.1016/j.jhep.2018.10.033. [Epub ahead of print]


  30. Association between vitamin D levels and nonalcoholic fatty liver disease: potential confounding variables
    Pacifico L1, Osborn JF2, Bonci E3, Pierimarchi P4, Chiesa C4. Mini Rev Med Chem. 2018 Oct 25. doi: 10.2174/1389557518666181025153712. [Epub ahead of print]


  31. Steatosis in Liver Transplantation: Current Limitations and Future Strategies
    Linares I1,2,3, Hamar M1,4, Selzner N1, Selzner M1. Transplantation. 2018 Nov 9. doi: 10.1097/TP.0000000000002466. [Epub ahead of print]


  32. Non-alcoholic fatty liver disease in underweight patients with inflammatory bowel disease: A case-control study
    Adams LC1, Lübbe F1, Bressem K1, Wagner M1, Hamm B1, Makowski MR1. PLoS One. 2018 Nov 14;13(11):e0206450. doi: 10.1371/journal.pone.0206450. eCollection 2018.


  33. The Future of Nonalcoholic Fatty Liver Disease Treatment
    Mazhar K1. Med Clin North Am. 2019 Jan;103(1):57-69. doi: 10.1016/j.mcna.2018.08.005. Epub 2018 Nov 1.


  34. Randomised clinical trial: emricasan versus placebo significantly decreases ALT and caspase 3/7 activation in subjects with non-alcoholic fatty liver disease
    Shiffman M1, Freilich B2, Vuppalanchi R3, Watt K4, Chan JL5, Spada A5, Hagerty DT5, Schiff E6. Aliment Pharmacol Ther. 2019 Jan;49(1):64-73. doi: 10.1111/apt.15030. Epub 2018 Nov 14.


  35. Non-alcoholic fatty liver disease and colorectal cancer survival
    Wu K1, Zhai MZ2, Weltzien EK3, Cespedes Feliciano EM3, Meyerhardt JA4, Giovannucci E5,6, Caan BJ3. Cancer Causes Control. 2018 Nov 15. doi: 10.1007/s10552-018-1095-z. [Epub ahead of print]


  36. Patient-reported outcomes for NAFLD/NASH: rational for expanded use
    Carrieri P1, Duracinsky M2,3,4, Marcellin F1, Lazarus JV5. Hepatology. 2018 Nov 25. doi: 10.1002/hep.30356. [Epub ahead of print]


  37. Non-alcoholic Steatohepatitis (NASH) Drug Discovery - Building a Consensus on ADME Screening Tools and Clinical Pharmacology Strategies to Aid Candidate Development
    Dash RP1, Babu RJ, Srinivas NR. J Pharm Pharm Sci. 2018;21(1):481-495. doi: 10.18433/jpps30022.


  38. Advances and challenges in the management of advanced fibrosis in nonalcoholic steatohepatitis
    Sayiner M1, Lam B2, Golabi P2, Younossi ZM3. Therap Adv Gastroenterol. 2018 Nov 15;11:1756284818811508. doi: 10.1177/1756284818811508. eCollection 2018.


  39. European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale
    Mann JP1, Vreugdenhil A2, Socha P3, Ja?czyk W3, Baumann U4, Rajwal S5, Casswall T6, Marcus C7, van Mourik I8, O'Rahilly S9, Savage DB9, Noble-Jamieson G10, Lacaille F11, Dabbas M11, Dubern B12, Kelly DA8, Nobili V13, Anstee QM14. Contemp Clin Trials. 2018 Dec;75:67-71. doi: 10.1016/j.cct.2018.11.003. Epub 2018 Nov 5.


  40. Clinical workup of fatty liver for the primary care provider
    Jensen T1, Wieland A2, Cree-Green M3, Nadeau K3, Sullivan S4. Postgrad Med. 2018 Nov 29:1-12. doi: 10.1080/00325481.2019.1546532. [Epub ahead of print]


  41. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Glass O1, Henao R2,3, Patel K4, Guy CD5, Gruss HJ6, Syn WK7,8, Moylan CA9, Streilein R10, Hall R10, Mae Diehl A9, Abdelmalek MF9. Hepatol Commun. 2018 Sep 21;2(11):1344-1355. doi: 10.1002/hep4.1237. eCollection 2018 Nov.


  42. Methods to improve the noninvasive diagnosis and assessment of disease severity in children with suspected nonalcoholic fatty liver disease (NAFLD): Study design
    Rudolph B1, Bjorklund N2, Ovchinsky N3, Kogan-Liberman D3, Perez A3, Liszewski M4, Levin TL4, Ewart M4, Liu Q4, Xue X5, Viswanathan S5, Strickler HD5. Contemp Clin Trials. 2018 Dec;75:51-58. doi: 10.1016/j.cct.2018.10.012. Epub 2018 Oct 27.


  43. Nonalcoholic Fatty Liver Disease
    Wang XJ1, Malhi H1. Ann Intern Med. 2018 Nov 6;169(9):ITC65-ITC80. doi: 10.7326/AITC201811060.


  44. Effects of Moderate Alcohol Drinking in Patients with Nonalcoholic Fatty Liver Disease
    Kwon I1, Jun DW2, Moon JH3. Gut Liver. 2018 Oct 30. doi: 10.5009/gnl18175. [Epub ahead of print]


  45. Obesity Drives STAT-1-Dependent NASH and STAT-3-Dependent HCC
    Grohmann M1, Wiede F2, Dodd GT1, Gurzov EN3, Ooi GJ4, Butt T1, Rasmiena AA5, Kaur S1, Gulati T5, Goh PK2, Treloar AE5, Archer S6, Brown WA4, Muller M7, Watt MJ3, Ohara O8, McLean CA9, Tiganis T10. Cell. 2018 Nov 15;175(5):1289-1306.e20. doi: 10.1016/j.cell.2018.09.053. Epub 2018 Oct 25.


  46. Targeting Metabolism, Insulin Resistance, and Diabetes to Treat Nonalcoholic Steatohepatitis
    Finck BN1. Diabetes. 2018 Dec;67(12):2485-2493. doi: 10.2337/dbi18-0024.


  47. BET Inhibition Improves NASH and Liver Fibrosis
    Middleton SA1, Rajpal N1, Cutler L2, Mander P3, Rioja I3, Prinjha RK3, Rajpal D1, Agarwal P1, Kumar V4. Sci Rep. 2018 Nov 22;8(1):17257. doi: 10.1038/s41598-018-35653-4.


  48. Validation of Serum Test for Advanced Liver Fibrosis in Patients with Nonalcoholic Steatohepatitis
    Loomba R1, Jain A2, Diehl AM3, Guy CD4, Portenier D5, Sudan R5, Singh S6, Faulkner C6, Richards L6, Hester KD2, Okada L2, Li XJ2, Mimms L2, Abdelmalek MF7. Clin Gastroenterol Hepatol. 2018 Nov 15. pii: S1542-3565(18)31247-3. doi: 10.1016/j.cgh.2018.11.004. [Epub ahead of print]


  49. Management of Recurrent and De Novo NAFLD/NASH after Liver Transplantation
    Germani G1, Laryea M2, Rubbia-Brandt L3, Egawa H4, Burra P1, O'Grady J5, Watt KD6. Transplantation. 2018 Oct 17. doi: 10.1097/TP.0000000000002485. [Epub ahead of print]


  50. Will Studies in Nonalcoholic Steatohepatitis Help Manage Alcoholic Steatohepatitis?
    Sundaram V1, Morgan TR2. Clin Liver Dis. 2019 Feb;23(1):157-165. doi: 10.1016/j.cld.2018.09.008.


  51. Causality between non-alcoholic fatty liver disease and risk of cardiovascular disease and type 2 diabetes: A meta-analysis with bias analysis
    Morrison AE1, Zaccardi F1,2, Khunti K1,2, Davies MJ1. Liver Int. 2018 Oct 25. doi: 10.1111/liv.13994. [Epub ahead of print]


  52. Hepatitis B virus infection is not associated with fatty liver disease: Evidence from a cohort study and functional analysis
    Wang B1, Li W1, Fang H1, Zhou H1. Mol Med Rep. 2018 Nov 2. doi: 10.3892/mmr.2018.9619. [Epub ahead of print]


  53. Non-alcoholic fatty liver disease: a narrative review of genetics
    Danford CJ1, Yao Z2, Jiang ZG1. J Biomed Res. 2018 Oct 24. doi: 10.7555/JBR.32.20180045. [Epub ahead of print]


  54. Association of non-alcoholic fatty liver disease with cardiovascular disease and subclinical atherosclerosis
    Sao R1, Aronow WS1. Arch Med Sci. 2018 Oct;14(6):1233-1244. doi: 10.5114/aoms.2017.68821. Epub 2017 Jul 5.


  55. A Novel Regulatory Role of Apoptosis Antagonizing Transcription Factor in the Pathogenesis of NAFLD and HCC
    Kumar DP1, Santhekadur PK1,2, Seneshaw M1, Mirshahi F1, Tuculescu CU3, Sanyal AJ1,2. Hepatology. 2018 Nov 5. doi: 10.1002/hep.30346. [Epub ahead of print]


  56. Relationship Between Three Commonly Used Non-invasive Fibrosis Biomarkers and Improvement in Fibrosis Stage in Patients With NASH
    Chalasani N1, Abdelmalek MF2, Loomba R3, Kowdley KV4, McCullough AJ5, Dasarathy S5, Neuschwander-Tetri BA6, Terrault N7, Ferguson B, Shringarpure R8, Shapiro D8, Sanyal AJ9. Liver Int. 2018 Sep 25. doi: 10.1111/liv.13974. [Epub ahead of print]


  57. Tie-ing up angiogenesis to treat NASH
    Davidson NO1. Hepatology. 2018 Oct 16. doi: 10.1002/hep.30318. [Epub ahead of print]


  58. Longitudinal analysis of risk of Non-Alcoholic Fatty Liver Disease (NAFLD) in adulthood
    Cuthbertson DJ1, Brown E1, Koskinen J2,3, Magnussen CG2,4, Hutri-Kähönen N5, Sabin M6,7, Tossavainen P8, Jokinen E9, Laitinen T10, Viikari J11,12, Raitakari OT2, Juonala M6,11,12. Liver Int. 2018 Oct 22. doi: 10.1111/liv.13993. [Epub ahead of print]


  59. Growth Hormone Deficiency and Nonalcoholic Fatty Liver Disease with Insights from Humans and Animals: Pediatric Implications
    Henry RK1. Metab Syndr Relat Disord. 2018 Oct 20. doi: 10.1089/met.2018.0056. [Epub ahead of print]


  60. NAFLD and liver transplantation in children - Working group report from the ILTS single topic conference on NAFLD
    Cananzi M1, Vajro P2, Rela M3, Dhawan A4. Transplantation. 2018 Oct 31. doi: 10.1097/TP.0000000000002490. [Epub ahead of print]


  61. Advances in Pediatric Fatty Liver Disease: Pathogenesis, Diagnosis, and Treatment
    Braun HA1, Faasse SA2, Vos MB2. Gastroenterol Clin North Am. 2018 Dec;47(4):949-968. doi: 10.1016/j.gtc.2018.07.016. Epub 2018 Sep 28.


  62. Chronic Kidney Disease is Independently Associated with Increased Mortality in Patients with Non-alcoholic Fatty Liver Disease
    Paik J1, Golabi P1, Younoszai Z1, Mishra A2, Trimble G2, Younossi ZM1. Liver Int. 2018 Oct 22. doi: 10.1111/liv.13992. [Epub ahead of print]


  63. Treatment of NASH with Gastric Bypass
    Jirapinyo P1,2, Thompson CC3,4. Curr Gastroenterol Rep. 2018 Sep 22;20(10):49. doi: 10.1007/s11894-018-0653-6.


  64. Micronutrients in Nonalcoholic Fatty Liver Disease Pathogenesis
    Pickett-Blakely O1, Young K1, Carr RM1. Cell Mol Gastroenterol Hepatol. 2018 Aug 23;6(4):451-462. doi: 10.1016/j.jcmgh.2018.07.004. eCollection 2018.


  65. The global prevalence and genetic spectrum of lysosomal acid lipase deficiency: a rare condition that mimics NAFLD
    Carter A1, Brackley SM2, Gao J3, Mann JP4. J Hepatol. 2018 Oct 10. pii: S0168-8278(18)32453-X. doi: 10.1016/j.jhep.2018.09.028. [Epub ahead of print]


  66. Long-term prognostic value of the FibroTest in patients with non-alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease
    Munteanu M1,2,3, Pais R2,3, Peta V1, Deckmyn O1, Moussalli J2, Ngo Y1, Rudler M2, Lebray P2, Charlotte F2, Thibault V2, Lucidarme O2,3, Ngo A2,3, Imbert-Bismut F2, Housset C3, Thabut D2,3, Ratziu V2,3, Poynard T2,3; FibroFrance Group. Aliment Pharmacol Ther. 2018 Nov;48(10):1117-1127. doi: 10.1111/apt.14990. Epub 2018 Oct 17.


  67. Nonalcoholic fatty liver disease (NAFLD): Diagnosis, pitfalls, and staging
    Koch LK1, Yeh MM2. Ann Diagn Pathol. 2018 Sep 27;37:83-90. doi: 10.1016/j.anndiagpath.2018.09.009. [Epub ahead of print]


  68. Rising Inpatient Encounters and Economic Burden for Patients with Nonalcoholic Fatty Liver Disease in the USA
    Nguyen MH1, Nguyen AL2, Park H3, Nguyen P4, Sheen E4, Kim YA4. Dig Dis Sci. 2018 Oct 16. doi: 10.1007/s10620-018-5326-7. [Epub ahead of print]


  69. The future R&D landscape in non-alcoholic steatohepatitis (NASH)
    Black D1, Brockbank S2, Cruwys S3, Goldenstein K2, Hein P2, Humphries B4. Drug Discov Today. 2018 Oct 3. pii: S1359-6446(18)30119-3. doi: 10.1016/j.drudis.2018.09.020. [Epub ahead of print]


  70. Epidemiology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis: Implications for Liver Transplantation
    Younossi ZM1, Marchesini G2, Pinto-Cortez H3, Petta S. Transplantation. 2018 Oct 17. doi: 10.1097/TP.0000000000002484. [Epub ahead of print]


  71. An internet-based approach for lifestyle changes in patients with NAFLD: Two-year effects on weight loss and surrogate markers
    Mazzotti A1, Caletti MT1, Brodosi L1, Di Domizio S1, Forchielli ML1, Petta S2, Bugianesi E3, Bianchi G1, Marchesini G4. J Hepatol. 2018 Nov;69(5):1155-1163. doi: 10.1016/j.jhep.2018.07.013. Epub 2018 Oct 2.


  72. Predictors of Nonalcoholic Steatohepatitis and Significant Fibrosis in Non-Obese Nonalcoholic Fatty Liver Disease
    Kim D1, Kim W2, Joo SK2, Kim JH3, Harrison SA4, Younossi ZM5, Ahmed A1. Liver Int. 2018 Oct 8. doi: 10.1111/liv.13983. [Epub ahead of print]


  73. Liver fat scores predict liver disease mortality in the United States population.
    Unalp-Arida A1, Ruhl CE2. Aliment Pharmacol Ther. 2018 Nov;48(9):1003-1016. doi: 10.1111/apt.14967. Epub 2018 Sep 18


  74. Hepatic Nuclear Receptor Expression Associates with Features of Histology in Pediatric Nonalcoholic Fatty Liver Disease
    Elbel EE1, Lavine JE1, Downes M2, Van Natta M3, Yu R2, Schwimmer JB4, Behling C4, Brunt EM5, Tonascia J3, Evans R2. Hepatol Commun. 2018 Sep 27;2(10):1213-1226. doi: 10.1002/hep4.1232. eCollection 2018 Oct.


  75. Among Patients With NAFLD, Treatment of Dyslipidemia Does Not Reduce Cardiovascular Mortality
    Shahab O1, Biswas R1, Paik J2, Bush H2, Golabi P2, Younossi ZM1,2. Hepatol Commun. 2018 Sep 24;2(10):1227-1234. doi: 10.1002/hep4.1241. eCollection 2018 Oct.


  76. NASH: The Emerging Most Common Form of Chronic Liver Disease
    Tesfay M1, Goldkamp WJ2, Neuschwander-Tetri BA3. Mo Med. 2018 May-Jun;115(3):225-229.


  77. Ultrasonographic Nonalcoholic Fatty Pancreas Is Associated with Advanced Fibrosis in NAFLD: A Retrospective Analysis
    Rosenblatt R1, Mehta A2, Snell D2, Hissong E3, Kierans AS4, Kumar S5. Dig Dis Sci. 2018 Sep 29. doi: 10.1007/s10620-018-5295-x. [Epub ahead of print]


  78. Emerging Therapeutic Targets and Experimental Drugs for the Treatment of NAFLD
    Dibba P1, Li AA2, Perumpail BJ3, John N4, Sallam S5, Shah ND6, Kwong W7, Cholankeril G8, Kim D9, Ahmed A10. Diseases. 2018 Sep 19;6(3). pii: E83. doi: 10.3390/diseases6030083.


  79. Effect of Body Mass Index, Metabolic Health and Adipose Tissue Inflammation on the Severity of Non-alcoholic Fatty Liver Disease in Bariatric Surgical Patients: a Prospective Study
    Ooi GJ1,2, Burton PR3,4, Bayliss J5,6, Raajendiran A5,6, Earnest A7, Laurie C3,4, Kemp WW8, McLean CA9, Roberts SK8, Watt MJ5,6, Brown WA3,4. Obes Surg. 2018 Sep 18. doi: 10.1007/s11695-018-3479-2. [Epub ahead of print]


  80. Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 Trials
    Connolly JJ1, Ooka K2, Lim JK3. J Clin Transl Hepatol. 2018 Sep 28;6(3):264-275. doi: 10.14218/JCTH.2017.00056. Epub 2018 Jun 28.


  81. When to Initiate Weight Loss Medications in the NAFLD Population
    Yoo ER1, Sallam S2, Perumpail BJ3, Iqbal U4, Shah ND5, Kwong W6, Cholankeril G7, Kim D8, Ahmed A9. Diseases. 2018 Sep 30;6(4). pii: E91. doi: 10.3390/diseases6040091.


  82. Obesity and nonalcoholic fatty liver disease: current perspectives
    Sarwar R1, Pierce N2, Koppe S3. Diabetes Metab Syndr Obes. 2018 Sep 25;11:533-542. doi: 10.2147/DMSO.S146339. eCollection 2018.


  83. Nonalcoholic Liver Disease in Children and Adolescents
    Smith SK1, Perito ER2. Clin Liver Dis. 2018 Nov;22(4):723-733. doi: 10.1016/j.cld.2018.07.001. Epub 2018 Aug 22.


  84. Factors Associated with Histologic Response in Adult Patients with Nonalcoholic Steatohepatitis
    Loomba R1, Sanyal AJ2, Kowdley KV3, Terrault N4, Chalasani NP5, Abdelmalek MF6, McCullough AJ7, Shringarpure R8, Ferguson B8, Lee L8, Chen J8, Liberman A8, Shapiro D8, Neuschwander-Tetri BA9. Gastroenterology. 2018 Sep 14. pii: S0016-5085(18)34977-1. doi: 10.1053/j.gastro.2018.09.021. [Epub ahead of print]


  85. An exploratory study examining how nano-liquid chromatography-mass spectrometry and phosphoproteomics can differentiate patients with advanced fibrosis and higher percentage collagen in non-alcoholic fatty liver disease
    Younossi ZM1,2,3, Karrar A4,5, Pierobon M6, Birerdinc A4, Stepanova M4,5, Abdelatif D4,7, Younoszai Z5, Jeffers T5, Felix S5, Jeiran K6, Hodge A6, Zhou W6, Monge F4,7, Alaparthi L4,7, Chandhoke V5,6, Goodman ZD4,7, Petricoin EF6. BMC Med. 2018 Sep 12;16(1):170. doi: 10.1186/s12916-018-1136-1.


  86. Mitochondrial role in the neonatal predisposition to developing nonalcoholic fatty liver disease
    Baker PR 2nd1, Friedman JE2,3,4. J Clin Invest. 2018 Aug 31;128(9):3692-3703. doi: 10.1172/JCI120846. Epub 2018 Aug 31.


  87. Overview of Updated Practice Guidelines for Pediatric Nonalcoholic Fatty Liver Disease
    Shah J1,2,3, Okubote T1,2,3, Alkhouri N1,2,3. Gastroenterol Hepatol (N Y). 2018 Jul;14(7):407-414.


  88. C-peptide as a key risk factor for non-alcoholic fatty liver disease in the United States population
    Atsawarungruangkit A1, Chenbhanich J1, Dickstein G1. World J Gastroenterol. 2018 Aug 28;24(32):3663-3670. doi: 10.3748/wjg.v24.i32.3663.


  89. Utility and variability of three non-invasive liver fibrosis imaging modalities to evaluate efficacy of GR-MD-02 in subjects with NASH and bridging fibrosis during a phase-2 randomized clinical trial
    Harrison SA1, Dennis A2, Fiore MM2, Kelly MD2, Kelly CJ2, Paredes AH3, Whitehead JM3, Neubauer S1,2, Traber PG4, Banerjee R2. PLoS One. 2018 Sep 7;13(9):e0203054. doi: 10.1371/journal.pone.0203054. eCollection 2018.


  90. Burden of Illness and Economic Model for Patients with Non-Alcoholic Steatohepatitis (NASH) in the United States
    Younossi ZM1,2, Tampi R1, Priyadarshini M1, Nader F3, Younossi IM3, Racila A1,3. Hepatology. 2018 Sep 4. doi: 10.1002/hep.30254. [Epub ahead of print]


  91. Putting non-alcoholic fatty liver disease on the radar for primary care physicians: how well are we doing?
    Sanyal AJ1,2. BMC Med. 2018 Aug 24;16(1):148. doi: 10.1186/s12916-018-1149-9.


  92. Current guidelines for the management of non-alcoholic fatty liver disease: A systematic review with comparative analysis
    Leoni S1, Tovoli F2, Napoli L2, Serio I2, Ferri S2, Bolondi L2. World J Gastroenterol. 2018 Aug 14;24(30):3361-3373. doi: 10.3748/wjg.v24.i30.3361.


  93. Role of the Circadian Clock in the Metabolic Syndrome and Nonalcoholic Fatty Liver Disease
    Shetty A1, Hsu JW1, Manka PP2, Syn WK3,4. Dig Dis Sci. 2018 Aug 18. doi: 10.1007/s10620-018-5242-x. [Epub ahead of print]


  94. Inter-reader agreement of magnetic resonance imaging proton density fat fraction and its longitudinal change in a clinical trial of adults with nonalcoholic steatohepatitis
    Hooker JC1, Hamilton G1, Park CC1, Liao S1, Wolfson T2, Dehkordy SF1, Hong CW1, Mamidipalli A1, Gamst A2, Loomba R3, Sirlin CB4. Abdom Radiol (NY). 2018 Aug 20. doi: 10.1007/s00261-018-1745-3. [Epub ahead of print]


  95. Different roles of FAT10, FOXO1, and ADRA2A in hepatocellular carcinoma tumorigenesis in patients with alcoholic steatohepatitis (ASH) vs non-alcoholic steatohepatitis (NASH)
    Jia Y1, French B2, Tillman B2, French S2. Exp Mol Pathol. 2018 Aug;105(1):144-149. doi: 10.1016/j.yexmp.2018.07.005. Epub 2018 Jul 17.


  96. Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?
    Hatton G1, Alterio T2, Nobili V2,3, Mann JP4,5. Expert Rev Gastroenterol Hepatol. 2018 Aug 21:1-7. doi: 10.1080/17474124.2018.1512853. [Epub ahead of print]


  97. Nuts and Cardiovascular Disease Prevention
    Coates AM1, Hill AM2, Tan SY3. Curr Atheroscler Rep. 2018 Aug 9;20(10):48. doi: 10.1007/s11883-018-0749-3.


  98. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models
    Green CJ1, Parry SA1, Gunn PJ1, Ceresa CDL1,2, Rosqvist F1,3, Piché ME1,4, Hodson L5. Horm Mol Biol Clin Investig. 2018 Aug 11. pii: /j/hmbci.ahead-of-print/hmbci-2018-0038/hmbci-2018-0038.xml. doi: 10.1515/hmbci-2018-0038. [Epub ahead of print]


  99. Prebiotic and probiotic treatment of nonalcoholic fatty liver disease: a systematic review and meta-analysis
    Loman BR1, Hernández-Saavedra D2, An R3, Rector RS4. Nutr Rev. 2018 Aug 3. doi: 10.1093/nutrit/nuy031. [Epub ahead of print]


  100. Real-world data reveal a diagnostic gap in non-alcoholic fatty liver disease
    Alexander M1, Loomis AK2, Fairburn-Beech J1, van der Lei J3, Duarte-Salles T4, Prieto-Alhambra D5, Ansell D6, Pasqua A7, Lapi F7, Rijnbeek P3, Mosseveld M3, Avillach P8, Egger P1, Kendrick S1, Waterworth DM1, Sattar N9, Alazawi W10. BMC Med. 2018 Aug 13;16(1):130. doi: 10.1186/s12916-018-1103-x.


  101. Global Perspectives on Non-alcoholic Fatty Liver Disease and Non-alcoholic Steatohepatitis
    Younossi Z1,2, Tacke F3, Arrese M4,5, Sharma BC6, Mostafa I7, Bugianesi E8, Wong VW9, Yilmaz Y10, George J11, Fan J12, Vos MB13. Hepatology. 2018 Sep 4. doi: 10.1002/hep.30251. [Epub ahead of print]


  102. The Conundrum of Cryptogenic Cirrhosis: Adverse Outcomes without Treatment Options
    Younossi Z1, Stepanova M2, Sanyal AJ3, Harrison SA4, Ratziu V5, Abdelmalek MF6, Diehl AM6, Caldwell S7, Shiffman ML8, Schall RA9, McColgan B9, Mani Subramanian G9, Myers RP9, Muir A6, Afdhal NH10, Bosch J11, Goodman Z2. J Hepatol. 2018 Aug 22. pii: S0168-8278(18)32295-5. doi: 10.1016/j.jhep.2018.08.013. [Epub ahead of print]


  103. Alcohol Consumption in Patients with Non-alcoholic Fatty Liver Disease: Convenient vs. Inconvenient Truths
    Armstrong MJ1,2,3, Mellinger JL4, Trivedi PJ5,6,7,8. Am J Gastroenterol. 2018 Aug 30. doi: 10.1038/s41395-018-0237-y. [Epub ahead of print]


  104. Waiting List Mortality and Transplant Rates for NASH Cirrhosis When Compared to Cryptogenic, Alcoholic or AIH Cirrhosis
    Thuluvath PJ1, Hanish S, Savva Y. Transplantation. 2018 Jul 5. doi: 10.1097/TP.0000000000002355. [Epub ahead of print]


  105. GS-0976 Reduces Hepatic Steatosis and Fibrosis Markers in Patients with Nonalcoholic Fatty Liver Disease
    Loomba R1, Kayali Z2, Noureddin M3, Ruane P4, Lawitz EJ5, Bennett M6, Wang L7, Harting E7, Tarrant JM7, McColgan BJ7, Chung C7, Ray AS7, Subramanian GM7, Myers RP7, Middleton MS8, Lai M9, Charlton M10, Harrison SA11. Gastroenterology. 2018 Jul 27. pii: S0016-5085(18)34815-7. doi: 10.1053/j.gastro.2018.07.027. [Epub ahead of print]


  106. Trimming the Fat: Acetyl-CoA Carboxylase Inhibition for the Management of NAFLD
    Imai N1, Cohen DE1. Hepatology. 2018 Aug 3. doi: 10.1002/hep.30206. [Epub ahead of print]


  107. Continuous Positive Airway Pressure Therapy on Nonalcoholic Fatty Liver Disease in Patients With Obstructive Sleep Apnea
    Kim D1, Ahmed A1, Kushida C2. J Clin Sleep Med. 2018 Aug 15;14(8):1315-1322. doi: 10.5664/jcsm.7262.


  108. Ad libitum Mediterranean or low fat diets as treatments for non-alcoholic fatty liver disease?
    Targher G1, Byrne CD2,3. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30142. [Epub ahead of print]


  109. Pathogenesis of NASH: How Metabolic Complications of Overnutrition Favour Lipotoxicity and Pro-Inflammatory Fatty Liver Disease
    Farrell GC1, Haczeyni F2, Chitturi S2. Adv Exp Med Biol. 2018;1061:19-44. doi: 10.1007/978-981-10-8684-7_3.


  110. Cognitive Performance in Individuals With NonAlcoholic Fatty Liver Disease and/or Type 2 Diabetes Mellitus
    Weinstein AA1, de Avila L2, Paik J2, Golabi P2, Escheik C2, Gerber L3, Younossi ZM4. Psychosomatics. 2018 Jun 10. pii: S0033-3182(18)30308-6. doi: 10.1016/j.psym.2018.06.001. [Epub ahead of print]


  111. Nonalcoholic fatty liver disease: current concepts, epidemiology and management strategies
    Tomic D1, Kemp WW, Roberts SK. Eur J Gastroenterol Hepatol. 2018 Aug 14. doi: 10.1097/MEG.0000000000001235. [Epub ahead of print]


  112. Chemokines and Chemokine Receptors in the Development of NAFLD
    Roh YS1, Seki E2. Adv Exp Med Biol. 2018;1061:45-53. doi: 10.1007/978-981-10-8684-7_4.


  113. Metabolomic-based noninvasive serum test to diagnose nonalcoholic steatohepatitis: Results from discovery and validation cohorts
    Mayo R1, Crespo J2, Martínez-Arranz I1, Banales JM3, Arias M2, Mincholé I1, Aller de la Fuente R4, Jimenez-Agüero R3, Alonso C1, de Luis DA5, Vitek L6, Stritesky J6, Caballería J7, Romero-Gómez M8, Martín-Duce A9, Mugüerza Huguet JM10, Busteros-Moraza JI11, Idowu MO12, Castro A1, Martínez-Chantar ML13, Ortiz P1, Bruha R6, Lu SC14, Bedossa P15, Noureddin M14, Sanyal AJ16, Mato JM13. Hepatol Commun. 2018 May 4;2(7):807-820. doi: 10.1002/hep4.1188. eCollection 2018 Jul.


  114. Nonalcoholic steatohepatitis, obesity, and cardiac dysfunction
    Mathews SE1, Kumar RB, Shukla AP. Curr Opin Endocrinol Diabetes Obes. 2018 Aug 1. doi: 10.1097/MED.0000000000000432. [Epub ahead of print]


  115. Patient-reported Outcomes and the Economic Effects of Non-Alcoholic Fatty Liver Diseaseand Non-alcoholic Steatohepatitis - The Value Proposition
    Younossi ZM1. Hepatology. 2018 Aug 2. doi: 10.1002/hep.30125. [Epub ahead of print]


  116. Non-alcoholic fatty liver disease-associated hepatocellular carcinoma: effect of hepatic steatosis on major hepatocellular carcinoma features at magnetic resonance imaging
    Thompson SM1, Garg I1, Ehman EC1, Sheedy SP1, Bookwalter CA1, Carter RE2, Roberts LR1, Venkatesh SK1. Br J Radiol. 2018 Aug 3:20180345. doi: 10.1259/bjr.20180345. [Epub ahead of print]


  117. Should patients with NAFLD/NASH be surveyed for HCC?
    Reig M1, Gambato M2, Man NK3, Roberts JP4, Victor D5, Orci LA6, Toso C6. Transplantation. 2018 Aug 4. doi: 10.1097/TP.0000000000002361. [Epub ahead of print]


  118. Simtuzumab Is Ineffective for Patients with Bridging Fibrosis or Compensated Cirrhosis Caused by Nonalcoholic Steatohepatitis
    Harrison SA1, Abdelmalek MF2, Caldwell S3, Shiffman ML4, Diehl AM2, Ghalib R5, Lawitz EJ6, Rockey DC7, Schall RA8, Jia C8, McColgan BJ8, McHutchison JG8, Subramanian GM8, Myers RP8, Younossi Z9, Ratziu V10, Muir AJ2, Afdhal NH11, Goodman Z9, Bosch J12, Sanyal AJ13; GS-US-321-0105GS-US-321-0106 Investigators. Gastroenterology. 2018 Jul 7. pii: S0016-5085(18)34758-9. doi: 10.1053/j.gastro.2018.07.006. [Epub ahead of print]


  119. Management of nonalcoholic fatty liver disease: Lessons learned from type 2 diabetes
    Alkhouri N1, Poordad F1, Lawitz E1. Hepatol Commun. 2018 Jun 7;2(7):778-785. doi: 10.1002/hep4.1195. eCollection 2018 Jul.


  120. Association Between Magnetic Resonance Imaging-Proton Density Fat Fraction and LiverHistology Features in Patients With Nonalcoholic Fatty Liver Disease or Nonalcoholic Steatohepatitis
    Wildman-Tobriner B1, Middleton MM2, Moylan CA3, Rossi S4, Flores O5, Chang ZA6, Abdelmalek MF7, Sirlin CB2, Bashir MR8. Gastroenterology. 2018 Jul 19. pii: S0016-5085(18)34784-X. doi: 10.1053/j.gastro.2018.07.018. [Epub ahead of print]


  121. Health benefits of Mediterranean diet in nonalcoholic fatty liver disease
    Abenavoli L1, Di Renzo L2, Boccuto L3, Alwardat N2, Gratteri S4, De Lorenzo A2. Expert Rev Gastroenterol Hepatol. 2018 Aug 1:1-9. doi: 10.1080/17474124.2018.1503947. [Epub ahead of print]


  122. Health-related quality of life burden of nonalcoholic steatohepatitis: a robust pragmatic literature review
    Kennedy-Martin T1, Bae JP2, Paczkowski R2, Freeman E2. J Patient Rep Outcomes. 2018 Jun 19;2:28. doi: 10.1186/s41687-018-0052-7. eCollection 2017.


  123. Changing Trends in Etiology-based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016
    Kim D1, Li AA2, Gadiparthi C3, Khan MA3, Cholankeril G4, Glenn JS4, Ahmed A4. Gastroenterology. 2018 Jul 12. pii: S0016-5085(18)34762-0. doi: 10.1053/j.gastro.2018.07.008. [Epub ahead of print]


  124. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study
    Eriksson JW1, Lundkvist P2, Jansson PA3, Johansson L4, Kvarnström M5, Moris L6, Miliotis T5, Forsberg GB5, Risérus U7, Lind L2, Oscarsson J5. Diabetologia. 2018 Sep;61(9):1923-1934. doi: 10.1007/s00125-018-4675-2. Epub 2018 Jul 3.


  125. Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
    Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print]


  126. Macrophages in Nonalcoholic Steatohepatitis: Friend or Foe?
    Grunhut J1, Wang W1, Aykut B1, Gakhal I1, Torres-Hernandez A1, Miller G1,2. Eur Med J Hepatol. 2018;6(1):100-109. Epub 2018 May 31.


  127. Mechanisms of NAFLD development and therapeutic strategies
    Friedman SL1, Neuschwander-Tetri BA2, Rinella M3, Sanyal AJ4. Nat Med. 2018 Jul;24(7):908-922. doi: 10.1038/s41591-018-0104-9. Epub 2018 Jul 2.


  128. Non-alcoholic Fatty Liver Disease: A Review of Anti-diabetic Pharmacologic Therapies
    Snyder HS1,2, Sakaan SA1,2, March KL1,2, Siddique O3, Cholankeril R4, Cummings CD1,2, Gadiparthi C5, Satapathy SK5, Ahmed A6, Cholankeril G5,6. J Clin Transl Hepatol. 2018 Jun 28;6(2):168-174. doi: 10.14218/JCTH.2017.00050. Epub 2018 Mar 25.


  129. Adiposity and gastrointestinal cancers: epidemiology, mechanisms and future directions
    Murphy N1, Jenab M1, Gunter MJ2. Nat Rev Gastroenterol Hepatol. 2018 Jul 3. doi: 10.1038/s41575-018-0038-1. [Epub ahead of print]


  130. A Case-control Study to Evaluate the Prevalence of Nonalcoholic Fatty Liver Disease Among Patients with Moderate-to-severe Psoriasis
    Awosika O1,2,3,4, Eleryan MG1,2,3,4, Rengifo-Pardo M1,2,3,4, Doherty L1,2,3,4, Martin LW1,2,3,4, Ehrlich A1,2,3,4. J Clin Aesthet Dermatol. 2018 Jun;11(6):33-37. Epub 2018 Jun 1.


  131. The characterisation of hepatic mitochondrial function in patients with non-alcoholic fatty liver disease (NAFLD) using the 13C-ketoisocaproate breath test
    Afolabi PR1, Scorletti E, Smith DE, Almehmadi AA, Calder PC, Byrne CD. J Breath Res. 2018 Jul 19;12(4):046002. doi: 10.1088/1752-7163/aacf12.


  132. Recent advances in understanding and managing non-alcoholic fatty liver disease
    Albhaisi S1, Sanyal A2. F1000Res. 2018 Jun 11;7. pii: F1000 Faculty Rev-720. doi: 10.12688/f1000research.14421.1. eCollection 2018.


  133. Inadequate Hepatocellular Carcinoma Screening in Patients With Nonalcoholic Steatohepatitis Cirrhosis
    Aby E1, Phan J1, Truong E1, Grotts J1, Saab S1,2. J Clin Gastroenterol. 2018 Jun 16. doi: 10.1097/MCG.0000000000001075. [Epub ahead of print]


  134. Non-alcoholic Steatohepatitis is the Fastest Growing Cause of Hepatocellular Carcinoma in Liver Transplant Candidates
    Younossi Z1, Stepanova M2, Ong JP3, Jacobson IM4, Bugianesi E5, Duseja A6, Eguchi Y7, Wong VW8, Negro F9, Yilmaz Y10, Romero-Gomez M11, George J12, Ahmed A13, Wong R14, Younossi I2, Ziayee M2, Afendy A2; Global NASH Council.. Clin Gastroenterol Hepatol. 2018 Jun 13. pii: S1542-3565(18)30611-6. doi: 10.1016/j.cgh.2018.05.057. [Epub ahead of print]


  135. Emricasan Improves Liver Function in Patients With Cirrhosis and High Model for End-stage Liver Disease Scores Compared With Placebo
    Frenette CT1, Morelli G2, Shiffman ML3, Frederick RT4, Rubin RA5, Fallon MB6, Cheng JT7, Cave M8, Khaderi SA9, Massoud O10, Pyrsopoulos N11, Park JS12, Robinson JM13, Yamashita M13, Spada AP13, Chan JL13, Hagerty DT13. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30622-0. doi: 10.1016/j.cgh.2018.06.012. [Epub ahead of print]


  136. Hepatic steatosis risk is partly driven by increased de novo lipogenesis following carbohydrate consumption
    Sanders FWB1, Acharjee A1,2, Walker C1, Marney L1, Roberts LD1,2,3, Imamura F4, Jenkins B1, Case J2, Ray S1,5, Virtue S6, Vidal-Puig A6, Kuh D7, Hardy R7, Allison M8, Forouhi N4, Murray AJ9, Wareham N4, Vacca M1,2,5,6, Koulman A1, Griffin JL10,1Genome Biol. 2018 Jun 20;19(1):79. doi: 10.1186/s13059-018-1439-8. 1.


  137. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation and fibrosis
    Hohenester S1, Christiansen S2, Nagel JM, Wimmer R1, Artmann R1, Denk G3, Bischoff M2, Bischoff G4, Rust C5. Am J Physiol Gastrointest Liver Physiol. 2018 Jun 7. doi: 10.1152/ajpgi.00044.2018. [Epub ahead of print]


  138. Pediatric Nonalcoholic Fatty Liver Disease in New York City: An Autopsy Study
    Fernandes DM1, Pantangi V2, Azam M3, Salomao M4, Iuga AC1, Lefkowitch JH1, Gill J5, Morotti R6, Lavine JE1, Mencin AA7. J Pediatr. 2018 Jun 11. pii: S0022-3476(18)30601-2. doi: 10.1016/j.jpeds.2018.04.047. [Epub ahead of print]


  139. The nonalcoholic fatty liver disease (NAFLD) fibrosis score, cardiovascular risk stratification and a strategy for secondary prevention with ezetimibe
    Simon TG1, Corey KE1, Cannon CP2, Blazing M3, Park JG4, O'Donoghue ML2, Chung RT1, Giugliano RP5.


  140. Histological improvement of non-alcoholic steatohepatitis with a prebiotic: a pilot clinical trial
    Bomhof MR1,2, Parnell JA3, Ramay HR4, Crotty P5, Rioux KP5,6, Probert CS7, Jayakumar S5, Raman M5, Reimer RA8,9. Eur J Nutr. 2018 May 19. doi: 10.1007/s00394-018-1721-2. [Epub ahead of print]


  141. Rates and Factors Associated With Placebo Response in Trials of Pharmacotherapies for Nonalcoholic Steatohepatitis: Systematic Review and Meta-analysis
    Thanda Han MA1, Altayar O2, Hamdeh S3, Takyar V4, Rotman Y4, Etzion O4, Lefebvre E5, Safadi R6, Ratziu V7, Prokop LJ8, Murad MH9, Noureddin M10. Clin Gastroenterol Hepatol. 2018 Jun 15. pii: S1542-3565(18)30621-9. doi: 10.1016/j.cgh.2018.06.011. [Epub ahead of print]


  142. NASH in Nondiabetic Endocrine Disorders
    Wang T1, Yang W1,2, Karakas S1,2, Sarkar S1,3. Metab Syndr Relat Disord. 2018 Jun 6. doi: 10.1089/met.2018.0044. [Epub ahead of print]


  143. Nonalcoholic fatty liver disease remission in men through regular exercise
    Osaka T1, Hashimoto Y1, Hamaguchi M2, Kojima T3, Obora A3, Fukui M1. J Clin Biochem Nutr. 2018 May;62(3):242-246. doi: 10.3164/jcbn.17-115. Epub 2018 Mar 17.


  144. Nonalcoholic fatty liver disease with elevated alanine aminotransferase levels is negatively associated with bone mineral density: Cross-sectional study in U.S. adults
    Umehara T1. PLoS One. 2018 Jun 13;13(6):e0197900. doi: 10.1371/journal.pone.0197900. eCollection 2018.


  145. Type and Pattern of Alcohol Consumption is Associated With Liver Fibrosis in Patients With Non-alcoholic Fatty Liver Disease
    Mitchell T1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Ching H2, Hamdorf J2, Adams LA4,5. Am J Gastroenterol. 2018 Jun 14. doi: 10.1038/s41395-018-0133-5. [Epub ahead of print]


  146. NASH Leading Cause of Liver Transplant in Women: Updated Analysis of Indications For Liver Transplant and Ethnic and Gender Variances
    Noureddin M1,2, Vipani A3, Bresee C4, Todo T5, Kim IK5, Alkhouri N6, Setiawan VW7, Tran T8,3, Ayoub WS8,3, Lu SC8,3, Klein AS5, Sundaram V8,3, Nissen NN5. Am J Gastroenterol. 2018 Jun 8. doi: 10.1038/s41395-018-0088-6. [Epub ahead of print]


  147. Lifestyle intervention for morbid obesity: effects on liver steatosis, inflammation and fibrosis
    Hohenester S1, Christiansen S2, Nagel JM, Wimmer R1, Artmann R1, Denk G3, Bischoff M2, Bischoff G4, Rust C5. Am J Physiol Gastrointest Liver Physiol. 2018 Jun 7. doi: 10.1152/ajpgi.00044.2018. [Epub ahead of print]


  148. Non-alcoholic fatty liver disease severity and metabolic complications in obese children: impact of omega-3 fatty acids
    Spahis S1, Alvarez F2, Ahmed N3, Dubois J4, Jalbout R5, Paganelli M5, Grzywacz K5, Delvin E5, Peretti N6, Levy E7. J Nutr Biochem. 2018 Apr 10;58:28-36. doi: 10.1016/j.jnutbio.2018.03.025. [Epub ahead of print]


  149. Omega-3 Fatty Acids and Fatty Liver Disease in Children
    Corte CD1, Iasevoli S2, Strologo AD3, Sanseviero M4, Nobili V5. Adv Food Nutr Res. 2018;85:59-77. doi: 10.1016/bs.afnr.2018.03.001. Epub 2018 Apr 12.


  150. Hepatic iron concentration correlates with insulin sensitivity in nonalcoholic fatty liver disease
    Britton L1,2,3,4, Bridle K1,2, Reiling J1,2,5, Santrampurwala N1,2,4, Wockner L4, Ching H6, Stuart K1,3, Subramaniam VN4,7, Jeffrey G6,8, St Pierre T9, House M9, Gummer J10, Trengove R10, Olynyk J11,12, Crawford D1,2, Adams L6,8. Hepatol Commun. 2018 Apr 27;2(6):644-653. doi: 10.1002/hep4.1190. eCollection 2018 Jun.


  151. Hepatic artery resistive index as surrogate marker for fibrosis progression in NAFLD patients: A clinical perspective
    Tana C1, Schiavone C2, Ticinesi A1, Lauretani F1, Nouvenne A1, Dietrich CF3, Meschi T1. Int J Immunopathol Pharmacol. 2018 Jan-Dec;32:2058738418781373. doi: 10.1177/2058738418781373.


  152. The Effect of a Hydrolyzed Polysaccharide Dietary Supplement on Biomarkers in Adults with Nonalcoholic Fatty Liver Disease
    Lewis JE1, Atlas SE1, Higuera OL1, Fiallo A1, Rasul A1, Farooqi A1, Kromo O2, Lantigua LA1, Tiozzo E1, Woolger JM3, Goldberg S4, Mendez A3, Rodriguez AE3, Konefal J5. Evid Based Complement Alternat Med. 2018 May 3;2018:1751583. doi: 10.1155/2018/1751583. eCollection 2018.


  153. Physical deconditioning is the common denominator in both obese and overweight subjects with nonalcoholic steatohepatitis
    Argo CK1, Stine JG1, Henry ZH1, Lackner C2, Patrie JT3, Weltman AL4, Caldwell SH1. Aliment Pharmacol Ther. 2018 May 24. doi: 10.1111/apt.14803. [Epub ahead of print]


  154. Identifying Nonalcoholic Fatty Liver Disease Advanced Fibrosis in the Veterans Health Administration
    Patel YA1, Gifford EJ2, Glass LM3,4, Turner MJ5, Han B5, Moylan CA6, Choi S6, Suzuki A6, Provenzale D6,5, Hunt CM6,5. Dig Dis Sci. 2018 May 19. doi: 10.1007/s10620-018-5123-3. [Epub ahead of print]


  155. Noninvasive Prediction of Esophageal Varices by Stiffness and Platelet in Nonalcoholic Fatty Liver Disease Cirrhosis
    Petta S1, Sebastiani G2, Bugianesi E3, Viganò M4, Wong VW5, Berzigotti A6, Fracanzani AL7, Anstee QM8, Marra F9, Barbara M10, Calvaruso V10, Cammà C10, Di Marco V10, Craxì A10, de Ledinghen V11. J Hepatol. 2018 May 23. pii: S0168-8278(18)32065-8. doi: 10.1016/j.jhep.2018.05.019. [Epub ahead of print]


  156. The role of intestinal microbiota in the pathogenesis of NAFLD: starting points for intervention
    Vespasiani-Gentilucci U1, Gallo P1, Picardi A1. Arch Med Sci. 2018 Apr;14(3):701-706. doi: 10.5114/aoms.2016.58831. Epub 2016 Mar 23.


  157. Alanine Aminotransferase as a Monitoring Biomarker in Children with Nonalcoholic Fatty Liver Disease: A Secondary Analysis Using TONIC Trial Data
    Arsik I1, Frediani JK2, Frezza D3, Chen W4, Ayer T5, Keskinocak P6, Jin R7, Konomi JV8, Barlow SE9, Xanthakos SA10, Lavine JE11, Vos MB12. Children (Basel). 2018 May 25;5(6). pii: E64. doi: 10.3390/children5060064.


  158. Gender Disparities in Liver Transplant Candidates with Non-Alcoholic Steatohepatitis
    Loy VM1, Joyce C1, Bello S1, VonRoenn N1, Cotler SJ1. Clin Transplant. 2018 May 27:e13297. doi: 10.1111/ctr.13297. [Epub ahead of print]


  159. Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Non-Alcoholic Fatty Liver Disease-a Systematic Review
    Mann JP1, Tang GY2, Nobili V3, Armstrong MJ4. Clin Gastroenterol Hepatol. 2018 May 29. pii: S1542-3565(18)30555-X. doi: 10.1016/j.cgh.2018.05.023. [Epub ahead of print]


  160. Healthcare Cost and Utilization in Nonalcoholic Fatty Liver Disease: Real-World Data from a Large US Claims Database
    Allen AM1, Van Houten HK2,3, Sangaralingham LR2,3, Talwalkar JA1,2, McCoy RG2,4,5. Hepatology. 2018 May 18. doi: 10.1002/hep.30094. [Epub ahead of print]


  161. Carbohydrates and diet patterns in nonalcoholic fatty liver disease in children and adolescents
    Sekkarie A1, Welsh JA, Vos MB. Curr Opin Clin Nutr Metab Care. 2018 Jul;21(4):283-288. doi: 10.1097/MCO.0000000000000476.


  162. Mechanistic Potential and Therapeutic Implications of Cannabinoids in Nonalcoholic Fatty Liver Disease
    Dibba P1, Li A2, Cholankeril G3, Iqbal U4, Gadiparthi C5, Khan MA6, Kim D7, Ahmed A8. Medicines (Basel). 2018 May 28;5(2). pii: E47. doi: 10.3390/medicines5020047.


  163. Modeling NAFLD Disease Burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030
    Estes C1, Anstee QM2, Arias-Loste MT3, Bantel H4, Bellentani S5, Caballeria J6, Colombo M7, Craxi A8, Crespo J9, Day CP2, Geier A10, Kondili LA11, Lazarus JV12, Loomba R13, Manns MP4, Marchesini G14, Negro F15, Petta S16, Ratziu V17, Romero-Gomez M18, Sanyal A19, Schattenberg JM20, Tacke F21, Trautwein C22, Wei L23, Zeuzem S24, Razavi H25. J Hepatol. 2018 Jun 7. pii: S0168-8278(18)32121-4. doi: 10.1016/j.jhep.2018.05.036. [Epub ahead of print]


  164. Analogy between non-alcoholic steatohepatitis (NASH) and hypertension: a stepwise patient-tailored approach for NASH treatment
    Ilan Y1. Ann Gastroenterol. 2018 May-Jun;31(3):296-304. doi: 10.20524/aog.2018.0248. Epub 2018 Mar 15.


  165. Alcohol Metabolism in the Progression of Human Nonalcoholic Steatohepatitis
    Li H1, Toth E1, Cherrington NJ1. Toxicol Sci. 2018 Apr 27. doi: 10.1093/toxsci/kfy106. [Epub ahead of print]


  166. Vitamin D status and associated genetic polymorphisms in a cohort of UK children with non-alcoholic fatty liver disease
    Gibson PS1,2, Quaglia A3, Dhawan A2, Wu H1, Lanham-New S1, Hart KH1, Fitzpatrick E2, Moore JB1,4. Pediatr Obes. 2018 May 14. doi: 10.1111/ijpo.12293. [Epub ahead of print]


  167. Non-alcoholic fatty liver disease and increased risk of all-cause mortality in elderly patients admitted for acute heart failure
    Valbusa F1, Agnoletti D1, Scala L1, Grillo C1, Arduini P2, Bonapace S3, Calabria S1, Scaturro G1, Mantovani A4, Zoppini G4, Turcato E2, Maggioni AP5, Arcaro G1, Targher G6. Int J Cardiol. 2018 May 2. pii: S0167-5273(18)30544-8. doi: 10.1016/j.ijcard.2018.04.129. [Epub ahead of print]


  168. US Time-Harmonic Elastography: Detection of Liver Fibrosis in Adolescents with Extreme Obesity with Nonalcoholic Fatty Liver Disease
    Hudert CA1, Tzschätzsch H1, Guo J1, Rudolph B1, Bläker H1, Loddenkemper C1, Luck W1, Müller HP1, Baumgart DC1, Hamm B1, Braun J1, Holzhütter HG1, Wiegand S1, Sack I1. Radiology. 2018 May 15:172928. doi: 10.1148/radiol.2018172928. [Epub ahead of print]


  169. Triggering and resolution of inflammation in NASH
    Schuster S1, Cabrera D2,3, Arrese M2,4, Feldstein AE5. Nat Rev Gastroenterol Hepatol. 2018 Jun;15(6):349-364. doi: 10.1038/s41575-018-0009-6.


  170. The Presence and Severity of Nonalcoholic Steatohepatitis Is Associated with Specific Changes in Circulating Bile Acids
    Gottlieb A, Bechmann L, Canbay A1. Ann Hepatol. 2018 May-June;17(3):340-341. doi: 10.5604/01.3001.0011.7378. Epub 2018 Apr 9.


  171. Nonalcoholic Fatty Liver Disease in Children: Not a Small Matter
    Conjeevaram Selvakumar PK1, Kabbany MN1, Alkhouri N2. Paediatr Drugs. 2018 May 9. doi: 10.1007/s40272-018-0292-2. [Epub ahead of print]


  172. Treating Obstructive Sleep Apnea and Chronic Intermittent Hypoxia Improves the Severity of Nonalcoholic Fatty Liver Disease in Children
    Sundaram SS1, Halbower AC2, Klawitter J3, Pan Z4, Robbins K5, Capocelli KE6, Sokol RJ5. J Pediatr. 2018 May 8. pii: S0022-3476(18)30375-5. doi: 10.1016/j.jpeds.2018.03.028. [Epub ahead of print]


  173. Liver fat imaging - a clinical overview of ultrasound, CT, and MR imaging
    Zhang Y1, Fowler KJ2, Hamilton G1, Cui J1, Sy EZ1, Balanay M1, Hooker JC1, Szeverenyi NM1, Sirlin CB1. Br J Radiol. 2018 May 3:20170959. doi: 10.1259/bjr.20170959. [Epub ahead of print]


  174. Risk of cardiomyopathy and cardiac arrhythmias in patients with nonalcoholic fatty liver disease
    Anstee QM1,2, Mantovani A3, Tilg H4, Targher G5. Nat Rev Gastroenterol Hepatol. 2018 Apr 30. doi: 10.1038/s41575-018-0010-0. [Epub ahead of print]


  175. Nonalcoholic Steatohepatitis: Histopathology Basics Within a Broader Context
    Schild MH1, Guy CD2. Surg Pathol Clin. 2018 Jun;11(2):267-285. doi: 10.1016/j.path.2018.02.013.


  176. Future of Treatment for Nonalcoholic Steatohepatitis: Can the Use of Safe, Evidence-Based, Clinically Proven Supplements Provide the Answer to the Unmet Need?
    Ilan Y1. Dig Dis Sci. 2018 Apr 20. doi: 10.1007/s10620-018-5080-x. [Epub ahead of print]


  177. Metabolic Features of Nonalcoholic Fatty Liver (NAFL) in Obese Adolescents: Findings from a Multi-ethnic Cohort
    Tricò D1,2, Caprio S3, Umano GR3,4, Pierpont B3, Nouws J3, Galderisi A3, Kim G5, Mata MM3, Santoro N3. Hepatology. 2018 Apr 17. doi: 10.1002/hep.30035. [Epub ahead of print]


  178. Non-alcoholic fatty liver disease: controlling an emerging epidemic, challenges, and future directions
    Ofosu A1, Ramai D1,2, Reddy M1. Ann Gastroenterol. 2018 May-Jun;31(3):288-295. doi: 10.20524/aog.2018.0240. Epub 2018 Feb 23.


  179. Acetyl-CoA Carboxylase Inhibitor GS-0976 for 12 Weeks Reduces Hepatic De Novo Lipogenesis and Steatosis in Patients with Nonalcoholic Steatohepatitis
    Lawitz EJ1, Coste A2, Poordad F2, Alkhouri N2, Loo N2, McColgan BJ3, Tarrant JM3, Nguyen T3, Han L3, Chung C3, Ray AS3, McHutchison JG3, Subramanian GM3, Myers RP3, Middleton MS4, Sirlin C4, Loomba R4, Nyangau E5, Fitch M5, Li K5, Hellerstein M5. Clin Gastroenterol Hepatol. 2018 Apr 26. pii: S1542-3565(18)30404-X. doi: 10.1016/j.cgh.2018.04.042. [Epub ahead of print]


  180. Dyslipidemia is associated with pediatric nonalcoholic fatty liver disease
    Dowla S1, Aslibekyan S2, Goss A3, Fontaine K4, Ashraf AP5. J Clin Lipidol. 2018 Apr 3. pii: S1933-2874(18)30194-6. doi: 10.1016/j.jacl.2018.03.089. [Epub ahead of print]


  181. Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Disease: Prevalence and Risk Factors
    Mariabeatrice P1, Andrea I1, Giuseppe L1, Michela M1, Endrit S1, Francesca A1, Rizzi SF1, La Fortezza RF1, Rosa L1, Antonella C1, Michele B1, Gioacchino L2, Enzo I1, Alfredo DL1. Inflamm Bowel Dis. 2018 Apr 23. doi: 10.1093/ibd/izy051. [Epub ahead of print]


  182. Leukocyte extracellular vesicle concentration is inversely associated with liverfibrosis severity in NAFLD
    Welsh JA1, Scorletti E1, Clough GF1, Englyst NA1, Byrne CD1,2. J Leukoc Biol. 2018 Mar 30. doi: 10.1002/JLB.5A1217-501R. [Epub ahead of print]


  183. The Biological Clock: A Pivotal Hub in Non-alcoholic Fatty Liver Disease Pathogenesis
    Mazzoccoli G1, De Cosmo S1, Mazza T2. Front Physiol. 2018 Mar 15;9:193. doi: 10.3389/fphys.2018.00193. eCollection 2018.


  184. Screening for therapeutic trials and treatment indication in clinical practice: MACK-3, a new blood test for the diagnosis of fibrotic NASH
    Boursier J1, Anty R2, Vonghia L3, Moal V1, Vanwolleghem T3, Canivet CM2, Michalak S1, Bonnafous S2, Michielsen P3, Oberti F1, Iannelli A2, Van Gaal L3, Patouraux S2, Blanchet O1, Verrijken A3, Gual P2, Rousselet MC1, Driessen A3, Hunault G1, Bertrais S1, Tran A2, Calès P1, Francque S3. Aliment Pharmacol Ther. 2018 May;47(10):1387-1396. doi: 10.1111/apt.14621. Epub 2018 Mar 25.


  185. Clinically Actionable Hypercholesterolemia and Hypertriglyceridemia in Children with Nonalcoholic Fatty Liver Disease
    Harlow KE1, Africa JA1, Wells A2, Belt PH3, Behling CA4, Jain AK5, Molleston JP6, Newton KP1, Rosenthal P7, Vos MB8, Xanthakos SA9, Lavine JE10, Schwimmer JB11; Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN). J Pediatr. 2018 Apr 13. pii: S0022-3476(18)30281-6. doi: 10.1016/j.jpeds.2018.02.038. [Epub ahead of print]


  186. NAFLD and HIV: Do Sex, Race, and Ethnicity Explain HIV-Related Risk?
    Soti S1, Corey KE2, Lake JE3, Erlandson KM4. Curr HIV/AIDS Rep. 2018 Apr 18. doi: 10.1007/s11904-018-0392-1. [Epub ahead of print]


  187. Novel link between gut-microbiome derived metabolite and shared gene-effects with hepatic steatosis and fibrosis in NAFLD
    Caussy C1,2, Hsu C1, Lo MT3, Liu A1, Bettencourt R1, Ajmera VH1, Bassirian S1, Hooker J4, Sy E4, Richards L1, Schork N5, Schnabl B1,6, Brenner DA1,6, Sirlin CB4, Chen CH3, Loomba R1,6,7; Genetics of NAFLD in Twins Consortium. Hepatology. 2018 Mar 23. doi: 10.1002/hep.29892. [Epub ahead of print]


  188. Specialized Proresolving Mediators: Enhancing Nonalcoholic Steatohepatitis and Fibrosis Resolution
    Musso G1, Gambino R2, Cassader M2, Paschetta E3, Sircana A4. Trends Pharmacol Sci. 2018 Apr;39(4):387-401. doi: 10.1016/j.tips.2018.01.003. Epub 2018 Feb 27.


  189. Fatty liver index is associated to pulse wave velocity in healthy subjects: Data from the Brisighella Heart Study
    Cicero AFG1, Gitto S2, Fogacci F3, Rosticci M3, Giovannini M3, D'Addato S3, Andreone P2, Borghi C3; Brisighella Heart Study Group Medical and Surgical Sciences Dept., University of Bologna. Eur J Intern Med. 2018 Mar 23. pii: S0953-6205(18)30126-2. doi: 10.1016/j.ejim.2018.03.010. [Epub ahead of print]


  190. Prevalence and Severity of NAFLD by Transient Elastography: Genetic and Metabolic Risk Factors in a General Population
    Petta S1, Di Marco V1, Pipitone RM1, Grimaudo S1, Buscemi C1, Craxì A1, Buscemi S2. Liver Int. 2018 Mar 25. doi: 10.1111/liv.13743. [Epub ahead of print]


  191. Circulating Interleukin-6 is a biomarker for coronary atherosclerosis in nonalcoholic fatty liver disease: Results from the Multi-Ethnic Study of Atherosclerosis
    Simon TG1, Trejo MEP2, McClelland R2, Bradley R3, Blaha MJ4, Zeb I5, Corey KE1, Budoff MJ6, Chung RT7. Int J Cardiol. 2018 May 15;259:198-204. doi: 10.1016/j.ijcard.2018.01.046.


  192. Nonalcoholic Fatty Liver is Contributing to the Increase in Cases of Liver Disease in US Emergency Departments
    Bush H1, Golabi P1, Otgonsuren M1, Rafiq N1,2, Venkatesan C2, Younossi ZM1,2. J Clin Gastroenterol. 2018 Mar 30. doi: 10.1097/MCG.0000000000001026. [Epub ahead of print]


  193. To die or not to die: death signaling in nonalcoholic fatty liver disease
    Akazawa Y1,2, Nakao K3. J Gastroenterol. 2018 Mar 24. doi: 10.1007/s00535-018-1451-5. [Epub ahead of print]


  194. A randomised, double-blind, placebo-controlled phase 1 study of the safety, tolerability and pharmacodynamics of volixibat in overweight and obese but otherwise healthy adults: implications for treatment of non-alcoholicsteatohepatitis
    Palmer M1, Jennings L2, Silberg DG3, Bliss C2, Martin P2. BMC Pharmacol Toxicol. 2018 Mar 16;19(1):10. doi: 10.1186/s40360-018-0200-y.


  195. Omega-3 fatty acids and non-alcoholic fatty liver disease: Evidence of efficacy and mechanism of action
    Scorletti E1, Byrne CD2. Mol Aspects Med. 2018 Mar 22. pii: S0098-2997(18)30019-0. doi: 10.1016/j.mam.2018.03.001. [Epub ahead of print]


  196. Non-alcoholic steatofibrosis (NASF) can independently predict mortality in patients with non-alcoholic fatty liver disease (NAFLD)
    Golabi P1, Stepanova M2, Pham HT1, Cable R1, Rafiq N1,3, Bush H1, Gogoll T1, Younossi ZM1,3. BMJ Open Gastroenterol. 2018 Mar 20;5(1):e000198. doi: 10.1136/bmjgast-2018-000198. eCollection 2018.


  197. Prevalence of Suspected Nonalcoholic Fatty Liver Disease In Lean Adolescents In The United States
    Selvakumar PKC1, Kabbany MN1, Lopez R2, Rayas MS3, Lynch JL3, Alkhouri N1,2,4,3. J Pediatr Gastroenterol Nutr. 2018 Mar 21. doi: 10.1097/MPG.0000000000001974. [Epub ahead of print]


  198. Gut microbiota in adolescents and the association with fatty liver: The EPOCH study
    Stanislawski MA1, Lozupone CA2, Wagner BD1, Eggesbø M3, Sontag MK1, Nusbacher N2, Martinez M1, Dabelea D1. Pediatr Res. 2018 Mar 14. doi: 10.1038/pr.2018.32. [Epub ahead of print]


  199. Increased risk of venous thromboembolism in hospitalized patients with cirrhosis due to non-alcoholic steatohepatitis
    Stine JG1,2, Niccum BA3, Zimmet AN3, Intagliata N4, Caldwell SH4, Argo CK4, Northup PG4. Clin Transl Gastroenterol. 2018 Mar 6;9(3):140. doi: 10.1038/s41424-018-0002-y.


  200. Analysis of genotyping for predicting liver injury marker, procollagen III in persons at risk of non-alcoholic fatty liver disease
    Grove JI1,2, Thiagarajan P1,2, Astbury S1,2, Harris R1,2, Delahooke T3, Guha IN1,2, Aithal GP1,2. Liver Int. 2018 Mar 1. doi: 10.1111/liv.13733. [Epub ahead of print]


  201. Geographic Variability in Liver Disease-Related Mortality Rates in the United States
    Desai AP1, Mohan P2, Roubal AM2, Bettencourt R3, Loomba R4. Am J Med. 2018 Feb 26. pii: S0002-9343(18)30127-X. doi: 10.1016/j.amjmed.2018.01.047. [Epub ahead of print]


  202. Diabetes impacts prediction of cirrhosis and prognosis by non-invasive fibrosis models in non-alcoholic fatty liver disease
    Bertot LC1, Jeffrey GP1,2, de Boer B3, MacQuillan G1,2, Garas G1,2, Chin J2, Huang Y1, Adams LA1,2. Liver Int. 2018 Mar 25. doi: 10.1111/liv.13739. [Epub ahead of print]


  203. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
    Tacke F1. Expert Opin Investig Drugs. 2018 Mar;27(3):301-311. doi: 10.1080/13543784.2018.1442436. Epub 2018 Feb 22.


  204. The sedentary (r)evolution: Have we lost our metabolic flexibility?
    Freese J1, Klement RJ2, Ruiz-Núñez B3, Schwarz S4, Lötzerich H1. Version 2. F1000Res. 2017 Oct 2 [revised 2018 Feb 2];6:1787. doi: 10.12688/f1000research.12724.2. eCollection 2017.


  205. Nonalcoholic Fatty Liver Disease in Children
    Mann JP1, Valenti L2, Scorletti E3, Byrne CD3,4,5, Nobili V6,7. Semin Liver Dis. 2018 Feb;38(1):1-13. doi: 10.1055/s-0038-1627456. Epub 2018 Feb 22.


  206. Protective effect of black relative to white race against non-alcoholic fatty liver disease in patients with severe obesity, independent of type 2 diabetes
    Browning MG1, Khoraki J2, DeAntonio JH2, Mazzini G2, Mangino MJ2, Siddiqui MS3, Wolfe LG2, Campos GM2. Int J Obes (Lond). 2017 Dec 21. doi: 10.1038/ijo.2017.309. [Epub ahead of print]


  207. Diagnosis of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: Why liver biopsy is essential
    Bedossa P1. Liver Int. 2018 Feb;38 Suppl 1:64-66. doi: 10.1111/liv.13653.


  208. Use of a Metabolomic Approach to Non-invasively Diagnose Nonalcoholic FattyLiver Disease in Patients with Type 2 Diabetes Mellitus
    Bril F1,2, Millán L3, Kalavalpalli S1, McPhaul MJ4, Caulfield MP4, Martinez-Arranz I3, Alonso C3, Ortiz Betes P3, Mato JM5, Cusi K1,2. Diabetes Obes Metab. 2018 Mar 12. doi: 10.1111/dom.13285. [Epub ahead of print]


  209. Non-alcoholic fatty liver disease, liver biomarkers and stroke risk: The Reasons for Geographic and Racial Differences in Stroke cohort
    Alexander KS1, Zakai NA1,2, Lidofsky SD1, Callas PW3, Judd SE4, Tracy RP2,5, Cushman M1,2. PLoS One. 2018 Mar 12;13(3):e0194153. doi: 10.1371/journal.pone.0194153. eCollection 2018.


  210. Digital liver biopsy: Bio-imaging of fatty liver for translational and clinical research
    Mancini M1, Summers P2, Faita F3, Brunetto MR4, Callea F5, De Nicola A6, Di Lascio N3, Farinati F7, Gastaldelli A8, Gridelli B9, Mirabelli P10, Neri E11, Salvadori PA3, Rebelos E4, Tiribelli C12, Valenti L13, Salvatore M10, Bonino F1. World J Hepatol. 2018 Feb 27;10(2):231-245. doi: 10.4254/wjh.v10.i2.231.


  211. Bariatric surgery as a treatment for metabolic syndrome
    Cordero P1, Li J, Oben JA. J R Coll Physicians Edinb. 2017 Dec;47(4):364-368. doi: 10.4997/JRCPE.2017.414.


  212. Cardiometabolic Effects of Anti-obesity Pharmacotherapy
    Crawford AR1, Alamuddin N1, Amaro A2. Curr Atheroscler Rep. 2018 Mar 6;20(4):18. doi: 10.1007/s11883-018-0719-9.


  213. Unanticipated Increases in Hepatic Steatosis among HIV Patients Receiving MR Antagonist Eplerenone for NAFLD
    Chaudhury CS1, Purdy JB2, Liu CY2, Morse CG2, Stanley TL3, Kleiner D4, Hadigan C1. Liver Int. 2018 Mar 6. doi: 10.1111/liv.13734. [Epub ahead of print]


  214. Developmental origins of non-alcoholic fatty liver disease as a risk factor for exaggerated metabolic and cardiovascular-renal disease
    Spradley FT1, Smith JA2, Alexander BT3, Anderson CD4. Am J Physiol Endocrinol Metab. 2018 Mar 6. doi: 10.1152/ajpendo.00394.2017. [Epub ahead of print]


  215. Patients with clinically metabolically healthy obesity are not necessarily healthy subclinically: further support for bariatric surgery in patients without metabolic disease?
    Haskins IN1, Chang J2, Nor Hanipah Z3, Singh T4, Mehta N4, McCullough AJ4, Brethauer SA2, Schauer PR2, Aminian A5. Surg Obes Relat Dis. 2018 Mar;14(3):342-346. doi: 10.1016/j.soard.2017.11.032. Epub 2017 Dec 8.


  216. Poor Survival after Retransplantation in NASH cirrhosis
    Thuluvath AJ1, Chen PH1, Thuluvath PJ1,1, Kantsevoy S1,1, Savva Y1. Transplantation. 2018 Feb 20. doi: 10.1097/TP.0000000000002135. [Epub ahead of print]


  217. NGM282 for treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial
    Harrison SA1, Rinella ME2, Abdelmalek MF3, Trotter JF4, Paredes AH5, Arnold HL6, Kugelmas M7, Bashir MR8, Jaros MJ9, Ling L10, Rossi SJ10, DePaoli AM10, Loomba R11. Lancet. 2018 Mar 5. pii: S0140-6736(18)30474-4. doi: 10.1016/S0140-6736(18)30474-4. [Epub ahead of print]


  218. De-novo nonalcoholic steatohepatitis is associated with long-term increased mortality in liver transplant recipients
    Gitto S1, de Maria N1, di Benedetto F2, Tarantino G2, Serra V2, Maroni L3, Cescon M3, Pinna AD3, Schepis F1, Andreone P4, Villa E1. Eur J Gastroenterol Hepatol. 2018 Mar 2. doi: 10.1097/MEG.0000000000001105. [Epub ahead of print]


  219. Can Elastography Differentiate Isolated Fatty Liver from Nonalcoholic Steatohepatitis?
    Ajmera V1, Loomba R1. Semin Liver Dis. 2018 Feb;38(1):14-20. doi: 10.1055/s-0037-1618587. Epub 2018 Feb 22.


  220. Ammonia: A novel target for the treatment of non-alcoholic steatohepatitis
    Thomsen KL1, De Chiara F2, Rombouts K2, Vilstrup H3, Andreola F2, Mookerjee RP2, Jalan R4. Med Hypotheses. 2018 Apr;113:91-97. doi: 10.1016/j.mehy.2018.02.010. Epub 2018 Feb 15.


  221. Diagnostic performance of a new noninvasive test for nonalcoholic steatohepatitis using a simplified histological reference
    Poynard T1,2, Munteanu M3, Charlotte F1, Perazzo H1,2, Ngo Y3, Deckmyn O3, Pais R1,2, Merrouche W4, de Ledinghen V4, Mathurin P4, Ratziu V1,2; for the FLIP Consortium, the FibroFrance-CPAM Group, the FibroFrance-Obese Group. Eur J Gastroenterol Hepatol. 2018 Feb 26. doi: 10.1097/MEG.0000000000001064. [Epub ahead of print]


  222. Management of patients with non-alcoholic steatohepatitis (NASH) in real life
    Serfaty L1. Liver Int. 2018 Feb;38 Suppl 1:52-55. doi: 10.1111/liv.13637.


  223. More Evidence for the Genetic Susceptibility of Mexican Population to Nonalcoholic Fatty Liver Disease through PNPLA3
    Chinchilla-López P1, Ramírez-Pérez O1, Cruz-Ramón V1, Canizales-Quinteros S2, Domínguez-López A3, Ponciano-Rodríguez G4, Sánchez-Muñoz F5, Méndez-Sánchez N1. Ann Hepatol. 2018 Mar 1;17(2):250-255. doi: 10.5604/01.3001.0010.8644.


  224. Pediatric Fatty Liver Disease (PeFLD): all is not NAFLD - pathophysiological insights and approach to management
    Hegarty R1, Deheragoda M2, Fitzpatrick E1, Dhawan A3. J Hepatol. 2018 Feb 19. pii: S0168-8278(18)30123-5. doi: 10.1016/j.jhep.2018.02.006. [Epub ahead of print]


  225. Evaluating feasibility and accuracy of non-invasive tests for nonalcoholic fattyliver disease in severe and morbid obesity
    Ooi GJ1,2, Earnest A3, Kemp WW4, Burton PR5,6, Laurie C5, Majeed A4, Johnson N7, McLean C8, Roberts SK4, Brown WA5,6. Int J Obes (Lond). 2018 Jan 30. doi: 10.1038/s41366-018-0007-3. [Epub ahead of print]


  226. Genetic Variants Associated With Obesity and Insulin Resistance in Hispanic Boys With Nonalcoholic Fatty Liver Disease
    Rausch JC1, Lavine JE1, Chalasani N2, Guo X3, Kwon S3, Schwimmer JB4, Molleston JP5, Loomba R6, Brunt EM7, Chen YI3, Goodarzi MO8, Taylor KD3, Yates KP9, Rotter JI3; NASH Clinical Research Network. J Pediatr Gastroenterol Nutr. 2018 Feb 21. doi: 10.1097/MPG.0000000000001926. [Epub ahead of print]


  227. Nonalcoholic steatofibrosis independently predicts mortality in nonalcoholic fatty liver disease
    Younossi ZM1,2, Stepanova M3,2, Rafiq N1,2, Henry L3,2, Loomba R4, Makhlouf H5, Goodman Z1,2. Hepatol Commun. 2017 Jun 6;1(5):421-428. doi: 10.1002/hep4.1054. eCollection 2017 Jul.


  228. Clinical endpoints and adaptive clinical trials in precirrhotic nonalcoholic steatohepatitis: Facilitating development approaches for an emerging epidemic
    Filozof C1, Chow SC2, Dimick-Santos L3, Chen YF3, Williams RN4, Goldstein BJ4, Sanyal A5. Hepatol Commun. 2017 Aug 1;1(7):577-585. doi: 10.1002/hep4.1079. eCollection 2017 Sep.


  229. DNA methylation signatures reflect aging in patients with nonalcoholic steatohepatitis
    Loomba R1, Gindin Y2, Jiang Z2, Lawitz E3, Caldwell S4, Djedjos CS2, Xu R2, Chung C2, Myers RP2, Subramanian GM2, Goodman Z5, Charlton M6, Afdhal NH7, Diehl AM8. JCI Insight. 2018 Jan 25;3(2). pii: 96685. doi: 10.1172/jci.insight.96685. [Epub ahead of print]


  230. Fructose and sugar: A major mediator of non-alcoholic fatty liver disease
    Jensen T1, Abdelmalek MF2, Sullivan S3, Nadeau KJ4, Green M4, Roncal C3, Nakagawa T5, Kuwabara M3, Sato Y3, Kang DH6, Tolan DR7, Sanchez-Lozada LG8, Rosen HR3, Lanaspa MA3, Diehl AM2, Johnson RJ3. J Hepatol. 2018 Feb 2. pii: S0168-8278(18)30066-7. doi: 10.1016/j.jhep.2018.01.019. [Epub ahead of print]


  231. Laboratory parameters in lean NAFLD: comparison of subjects with lean NAFLDwith obese subjects without hepatic steatosis
    Bernhardt P1, Kratzer W2, Schmidberger J1, Graeter T3, Gruener B4; EMIL Study Group. Collaborators (47) BMC Res Notes. 2018 Feb 6;11(1):101. doi: 10.1186/s13104-018-3212-1.


  232. Nonalcoholic fatty liver disease and the ongoing role of liver biopsy evaluation
    Brunt EM1. Hepatol Commun. 2017 Jun 7;1(5):370-378. doi: 10.1002/hep4.1055. eCollection 2017 Jul.


  233. Effects of dark chocolate on endothelial function in patients with non-alcoholic steatohepatitis
    Loffredo L1, Baratta F2, Ludovica P2, Battaglia S2, Carnevale R2, Nocella C2, Novo M2, Pannitteri G3, Ceci F4, Angelico F5, Violi F2, Del Ben M2. Nutr Metab Cardiovasc Dis. 2018 Feb;28(2):143-149. doi: 10.1016/j.numecd.2017.10.027. Epub 2017 Nov 13.


  234. Use of Mac-2 binding protein as a biomarker for nonalcoholic fatty liver disease diagnosis
    Kamada Y1,2, Ono M3, Hyogo H4, Fujii H5, Sumida Y6, Yamada M7, Mori K8, Tanaka S8, Maekawa T1, Ebisutani Y1, Yamamoto A1, Takamatsu S1, Yoneda M6, Kawada N5, Chayama K9, Saibara T3, Takehara T2, Miyoshi E1; Japan Study Group of Nonalcoholic Fatty Liver Disease (JSG?NAFLD). Hepatol Commun. 2017 Aug 16;1(8):780-791. doi: 10.1002/hep4.1080. eCollection 2017 Oct.


  235. Noninvasive imaging biomarker assessment of liver fibrosis by elastography in NAFLD
    Tapper EB1,2,3, Loomba R4,5. Nat Rev Gastroenterol Hepatol. 2018 Feb 21. doi: 10.1038/nrgastro.2018.10. [Epub ahead of print]


  236. Differing clinical phenotype for higher alanine-aminotransferase (ALT) compared with high-risk NAFLD fibrosis score in type 2 diabetes mellitus
    Williams KH1, Burns K2, Twigg SM3. J Diabetes Complications. 2017 Dec 29. pii: S1056-8727(17)31262-X. doi: 10.1016/j.jdiacomp.2017.12.010. [Epub ahead of print]


  237. Assessment of Fatty Liver in Models of Disease Programming
    Bruce KD1, Jonscher KR2. Methods Mol Biol. 2018;1735:251-266. doi: 10.1007/978-1-4939-7614-0_15.


  238. Arsenic exposure and risk of nonalcoholic fatty liver disease (NAFLD) among U.S. adolescents and adults: an association modified by race/ethnicity, NHANES 2005-2014
    Frediani JK1, Naioti EA2, Vos MB1, Figueroa J1, Marsit CJ3, Welsh JA4,5. Environ Health. 2018 Jan 15;17(1):6. doi: 10.1186/s12940-017-0350-1.


  239. Improvement of Hepatic Fibrosis and Patient-Reported Outcomes in Non-Alcoholic Steatohepatitis Treated with Selonsertib
    Younossi ZM1, Stepanova M2, Lawitz E3, Charlton M4, Loomba R5, Myers RP6, Subramanian GM6, McHutchison JG6, Goodman Z7. Liver Int. 2018 Jan 27. doi: 10.1111/liv.13706. [Epub ahead of print]


  240. Liver diseases: A major, neglected global public health problem requiring urgent actions and large-scale screening
    Marcellin P1, Kutala BK1. Liver Int. 2018 Feb;38 Suppl 1:2-6. doi: 10.1111/liv.13682.


  241. A simple clinical model predicts incident hepatic steatosis in a community-based cohort: The Framingham Heart Study
    Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Ma J2, Loomba R6,7,8, Chung RT9, Benjamin EJ2,10,11. Liver Int. 2018 Jan 29. doi: 10.1111/liv.13709. [Epub ahead of print]


  242. Non-alcoholic steatohepatitis pathogenesis: sublethal hepatocyte injury as a driver of liver inflammation
    Ibrahim SH1,2, Hirsova P3,4, Gores GJ2. Gut. 2018 Jan 24. pii: gutjnl-2017-315691. doi: 10.1136/gutjnl-2017-315691. [Epub ahead of print]


  243. Translating scientific discovery: the need for preclinical models of nonalcoholic steatohepatitis
    Oseini AM1, Cole BK2, Issa D3, Feaver RE2, Sanyal AJ3,4. Hepatol Int. 2018 Jan 3. doi: 10.1007/s12072-017-9838-6. [Epub ahead of print]


  244. Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: Implications for liver transplantation
    Younossi ZM1,2. Liver Transpl. 2018 Feb;24(2):166-170. doi: 10.1002/lt.25003.


  245. Vitamin E as a Treatment for Nonalcoholic Fatty Liver Disease: Reality or Myth?
    El Hadi H1, Vettor R2, Rossato M3. Antioxidants (Basel). 2018 Jan 16;7(1). pii: E12. doi: 10.3390/antiox7010012.


  246. Silymarin: An option to treat non-alcoholic fatty liver disease
    Colica C1, Boccuto L2, Abenavoli L3. World J Gastroenterol. 2017 Dec 21;23(47):8437-8438. doi: 10.3748/wjg.v23.i47.8437.


  247. Predictors of Non-Alcoholic Liver Disease in Ethnically Diverse Overweight Children and Adolescents
    Botero P1. Curr Pediatr Rev. 2018 Jan 23. doi: 10.2174/1573396314666180124101521. [Epub ahead of print]


  248. Origins of Portal Hypertension in Nonalcoholic Fatty Liver Disease
    Baffy G1. Dig Dis Sci. 2018 Jan 22. doi: 10.1007/s10620-017-4903-5. [Epub ahead of print]


  249. Liver transplantation for non-alcoholic fatty liver disease
    Germani G1, Becchetti C2. Minerva Gastroenterol Dietol. 2017 Dec 15. doi: 10.23736/S1121-421X.17.02467-9. [Epub ahead of print]


  250. Treating nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a review of efficacy and safety
    Mills EP1, Brown KPD2, Smith JD3, Vang PW2, Trotta K2. Ther Adv Endocrinol Metab. 2018 Jan;9(1):15-28. doi: 10.1177/2042018817741852. Epub 2017 Dec 7.


  251. Pediatric Nonalcoholic Fatty Liver Disease: Current Thinking
    Nobili V1,2, Socha P3. J Pediatr Gastroenterol Nutr. 2018 Feb;66(2):188-192. doi: 10.1097/MPG.0000000000001823.


  252. Non-invasive, quantitative assessment of liver fat by MRI-PDFF as an endpoint in NASH trials
    Caussy C1,2, Reeder SB3, Sirlin CB4, Loomba R1,5,6. Hepatology. 2018 Jan 21. doi: 10.1002/hep.29797. [Epub ahead of print]


  253. New scoring system combining the FIB-4 index and cytokeratin-18 fragments for predicting steatohepatitis and liver fibrosis in patients with nonalcoholic fattyliver disease
    Tada T1, Kumada T1, Toyoda H1, Saibara T2, Ono M2, Kage M3. Biomarkers. 2018 Jan 19:1-7. doi: 10.1080/1354750X.2018.1425915. [Epub ahead of print]


  254. Association between obstructive sleep apnea and non-alcoholic fatty liver disease: a systematic review and meta-analysis
    Jin S1, Jiang S2, Hu A3,4. Sleep Breath. 2018 Jan 15. doi: 10.1007/s11325-018-1625-7. [Epub ahead of print]


  255. Nonalcoholic steatohepatitis: the new frontier for liver transplantation
    Bzowej NH1. Curr Opin Organ Transplant. 2018 Jan 19. doi: 10.1097/MOT.0000000000000502. [Epub ahead of print]


  256. Obese children with fatty liver: Between reality and disease mongering
    Ranucci G1, Spagnuolo MI1, Iorio R2. World J Gastroenterol. 2017 Dec 21;23(47):8277-8282. doi: 10.3748/wjg.v23.i47.8277.


  257. Low Circulating Levels of Neurotensin in Women with Nonalcoholic Fatty LiverDisease Associated with Severe Obesity
    Auguet T1,2, Aragonès G1, Berlanga A1, Martínez S3, Sabench F4, Aguilar C1, Villar B2, Sirvent JJ3, Del Castillo D4, Richart C1,2. Obesity (Silver Spring). 2018 Feb;26(2):274-278. doi: 10.1002/oby.22058. Epub 2017 Dec 25.


  258. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease
    Perumpail BJ1, Khan MA2, Yoo ER3, Cholankeril G4, Kim D4, Ahmed A5. World J Gastroenterol. 2017 Dec 21;23(47):8263-8276. doi: 10.3748/wjg.v23.i47.8263.


  259. An updated meta-analysis of pioglitazone exposure and bladder cancer and comparison to the drug's effect on cardiovascular disease and non-alcoholic steatohepatitis
    Davidson MB1, Pan D2. Diabetes Res Clin Pract. 2017 Nov 13;135:102-110. doi: 10.1016/j.diabres.2017.11.002. [Epub ahead of print]


  260. Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH)
    Tully DC1,2, Rucker PV1, Chianelli D1, Williams J1, Vidal A1, Alper PB1, Mutnick D1, Bursulaya B1, Schmeits J1, Wu X1, Bao D1, Zoll J1, Kim Y1, Groessl T1, McNamara P1, Seidel HM1, Molteni V1, Liu B1, Phimister A2, Joseph SB1, Laffitte B1. J Med Chem. 2017 Dec 28;60(24):9960-9973. doi: 10.1021/acs.jmedchem.7b00907. Epub 2017 Dec 8.


  261. Clinical and metabolic effects associated with weight changes and obeticholic acid in non-alcoholic steatohepatitis
    Hameed B1, Terrault NA1, Gill RM1, Loomba R2, Chalasani N3, Hoofnagle JH4, Van Natta ML5; NASH CRN. Aliment Pharmacol Ther. 2018 Jan 14. doi: 10.1111/apt.14492. [Epub ahead of print]


  262. Liver transplantation for NASH-related hepatocellular carcinoma versus non-NASH etiologies of hepatocellular carcinoma
    Sadler EM1,1, Mehta N1, Bhat M1,1, Ghanekar A1,1, Greig PD1,1, Grant DR1,1, Yao F1, Sapisochin G1,1. Transplantation. 2018 Jan 10. doi: 10.1097/TP.0000000000002043. [Epub ahead of print]


  263. Alcoholic hepatitis versus non-alcoholic steatohepatitis: Levels of expression of some proteins involved in tumorigenesis
    Nguyen L1, Masouminia M2, Mendoza A2, Samadzadeh S2, Tillman B2, Morgan T3, French B2, French S2. Exp Mol Pathol. 2018 Jan 4;104(1):45-49. doi: 10.1016/j.yexmp.2017.12.007. [Epub ahead of print]


  264. Epidemic of non-alcoholic fatty liver disease and hepatocellular carcinoma
    Said A1, Ghufran A2. World J Clin Oncol. 2017 Dec 10;8(6):429-436. doi: 10.5306/wjco.v8.i6.429.


  265. Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
    Targher G1, Lonardo A2, Byrne CD3,4. Nat Rev Endocrinol. 2018 Feb;14(2):99-114. doi: 10.1038/nrendo.2017.173. Epub 2017 Dec 29.


  266. Prevention of Tamoxifen-related Nonalcoholic Fatty Liver Disease in Breast Cancer Patients
    Chang HT1, Pan HJ2, Lee CH3. Clin Breast Cancer. 2017 Nov 23. pii: S1526-8209(17)30357-9. doi: 10.1016/j.clbc.2017.11.010. [Epub ahead of print]


  267. Impact of steatosis and inflammation definitions on the performance of NASHtests
    Poynard T1,2,3, Munteanu M4, Charlotte F1,2, Perazzo H1,2,3, Ngo Y4, Deckmyn O4, Pais R1,2,3, Mathurin P5, Ratziu V1,2,3; for the FLIP consortium, the FibroFrance-CPAM group; and the FibroFrance-Obese group. Eur J Gastroenterol Hepatol. 2017 Dec 26. doi: 10.1097/MEG.0000000000001033. [Epub ahead of print]


  268. Current and future pharmacological therapies for NAFLD/NASH
    Sumida Y1, Yoneda M2. J Gastroenterol. 2017 Dec 16. doi: 10.1007/s00535-017-1415-1. [Epub ahead of print]


  269. Fatty acids in non-alcoholic steatohepatitis: Focus on pentadecanoic acid
    Yoo W1, Gjuka D1, Stevenson HL2, Song X3, Shen H1, Yoo SY4, Wang J4, Fallon M5, Ioannou GN6, Harrison SA7, Beretta L1. PLoS One. 2017 Dec 15;12(12):e0189965. doi: 10.1371/journal.pone.0189965. eCollection 2017.


  270. Clinical course of nonalcoholic fatty liver disease: an assessment of severity, progression, and outcomes
    Simeone JC1, Bae JP2, Hoogwerf BJ3, Li Q1, Haupt A3, Ali AK4, Boardman MK3, Nordstrom BL1. Clin Epidemiol. 2017 Dec 14;9:679-688. doi: 10.2147/CLEP.S144368. eCollection 2017.


  271. Utility and cost evaluation of multiparametric magnetic resonance imaging for the assessment of non-alcoholic fatty liver disease
    Eddowes PJ1, McDonald N2, Davies N1, Semple SIK2, Kendall TJ2, Hodson J1, Newsome PN1, Flintham RB1, Wesolowski R1, Blake L1, Duarte RV3, Kelly CJ4, Herlihy AH4, Kelly MD4, Olliff SP1, Hübscher SG1, Fallowfield JA2, Hirschfield GM1. Aliment Pharmacol Ther. 2017 Dec 22. doi: 10.1111/apt.14469. [Epub ahead of print]


  272. Relationship between Hypothyroidism and Non-Alcoholic Fatty Liver Disease: A Systematic Review and Meta-analysis
    He W1, An X2, Li L2, Shao X2, Li Q2, Yao Q2, Zhang JA3. Front Endocrinol (Lausanne). 2017 Nov 29;8:335. doi: 10.3389/fendo.2017.00335. eCollection 2017.


  273. Association between nonalcoholic fatty liver disease and subclinical coronary atherosclerosis: An observational cohort study
    Lee SB1, Park GM2, Lee JY3, Lee BU1, Park JH1, Kim BG1, Jung SW1, Jeong ID1, Bang SJ1, Shin JW1, Park NH1, Yang DH4, Kang JW4, Lim TH4, Kim HK5, Choe J5, Lee HC6. J Hepatol. 2017 Dec 20. pii: S0168-8278(17)32527-8. doi: 10.1016/j.jhep.2017.12.012. [Epub ahead of print]


  274. Non-Alcoholic Fatty Liver Disease and HIV/AIDS: A New Way of Modulation of Cardiovascular Risk
    Ahmed MH1, Husain NE2, Malik A3, Woodward C4, Mital D4. AIDS Rev. 2017 Oct-Dec;19(4):190-197.


  275. Clinical relevance of liver histopathology and different histological classifications of NASH in adults
    Nascimbeni F1,2, Ballestri S3, Machado MV4, Mantovani A5, Cortez-Pinto H4, Targher G5, Lonardo A1. Expert Rev Gastroenterol Hepatol. 2017 Dec 26:1-17. doi: 10.1080/17474124.2018.1415756. [Epub ahead of print]


  276. Hepatitis, Nonalcoholic Steatohepatitis
    Sharma B1, John S2.


  277. Liver Transplantation in Cryptogenic Cirrhosis: Outcome comparisons between NASH, Alcoholic and AIH cirrhosis
    Thuluvath PJ1, Hanish S, Savva Y. Transplantation. 2017 Dec 5. doi: 10.1097/TP.0000000000002030. [Epub ahead of print]


  278. Non-alcoholic Fatty Liver Disease: A Clinical Update
    Pappachan JM1, Babu S2, Krishnan B3, Ravindran NC4. J Clin Transl Hepatol. 2017 Dec 28;5(4):384-393. doi: 10.14218/JCTH.2017.00013. Epub 2017 Jul 26.


  279. Too much medicine: overdiagnosis and overtreatment of non-alcoholic fatty liver disease
    Rowe IA1. Lancet Gastroenterol Hepatol. 2018 Jan;3(1):66-72. doi: 10.1016/S2468-1253(17)30142-5.


  280. Liver fat content, non-alcoholic fatty liver disease, and ischaemic heart disease: Mendelian randomization and meta-analysis of 279?013 individuals
    Lauridsen BK1,2, Stender S1,2, Kristensen TS2,3, Kofoed KF2,4, Køber L2,4, Nordestgaard BG2,5,6,7, Tybjærg-Hansen A1,2,5,7. Eur Heart J. 2017 Dec 8. doi: 10.1093/eurheartj/ehx662. [Epub ahead of print]


  281. Effect of aerobic exercise and diet on liver fat in pre-diabetic patients with non-alcoholic-fatty-liver-disease: A randomized controlled trial
    Cheng S1,2,3, Ge J4, Zhao C5, Le S6, Yang Y6, Ke D5, Wu N6, Tan X6,7, Zhang X6, Du X4, Sun J8, Wang R5, Shi Y9, Borra RJH10,11, Parkkola R10, Wiklund P7,12,13, Lu D14. Sci Rep. 2017 Nov 21;7(1):15952. doi: 10.1038/s41598-017-16159-x.


  282. Alcohol Consumption in Diabetic Patients with Nonalcoholic Fatty Liver Disease
    Patel PJ1,2, Smith D3, Connor JP4, Horsfall LU1,2, Hayward KL2, Hossain F5, Williams S5, Johnson T5, Stuart KA1, Brown NN6, Saad N7, Clouston AD2, Irvine KM2,8, Russell AW9,10, Valery PC2,3,9, Powell EE1,2. Can J Gastroenterol Hepatol. 2017;2017:7927685. doi: 10.1155/2017/7927685. Epub 2017 Nov 1.


  283. Response to Pioglitazone in Patients With Nonalcoholic Steatohepatitis With vs Without Type 2 Diabetes
    Bril F1, Kalavalapalli S2, Clark VC3, Lomonaco R1, Soldevila-Pico C3, Liu IC2, Orsak B4, Tio F5, Cusi K6. Clin Gastroenterol Hepatol. 2017 Dec 6. pii: S1542-3565(17)31424-6. doi: 10.1016/j.cgh.2017.12.001. [Epub ahead of print]


  284. A critical review of endpoints for non-cirrhotic NASH therapeutic trials
    Ratziu V1. J Hepatol. 2017 Dec 6. pii: S0168-8278(17)32481-9. doi: 10.1016/j.jhep.2017.12.001. [Epub ahead of print]


  285. The sedentary (r)evolution: Have we lost our metabolic flexibility?
    Freese J1, Klement RJ2, Ruiz-Núñez B3, Schwarz S4, Lötzerich H1. F1000Res. 2017 Oct 2;6:1787. doi: 10.12688/f1000research.12724.1. eCollection 2017.


  286. Fibromax-based nonalcoholic fatty liver disease in chronic obstructive pulmonary disease patients with obstructive sleep apnea: Methodological considerations
    Monneret D1. F1000Res. 2017 Sep 8;6:1669. doi: 10.12688/f1000research.12581.1. eCollection 2017.


  287. Diagnostic Modalities for Non-alcoholic Fatty Liver Disease (NAFLD), Non-alcoholic Steatohepatitis (NASH) and Associated Fibrosis
    Younossi ZM1, Loomba R2, Anstee QM3, Rinella ME4, Bugianesi E5, Marchesini G6, Neuschwander-Tetri BA7, Serfaty L8, Negro F9, Caldwell SH10, Ratziu V11, Corey KE12, Friedman SL13, Abdelmalek MF14, Harrison SA15, Sanyal AJ16, Lavine JE17, Mathurin P18, Charlton MR19, Goodman ZD1, Chalasani NP9,20, Kowdley KV21, George J22, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29721. [Epub ahead of print]


  288. Liver zonation in children with NAFLD: associations with dietary fructose and uric acid concentrations
    Nobili V1,2, Mosca A1, De Vito R3, Raponi M4, Scorletti E5, Byrne CD5,6. Liver Int. 2017 Dec 9. doi: 10.1111/liv.13661. [Epub ahead of print]


  289. Current and Future Therapeutic Regimens for Non-alcoholic Fatty Liver Disease (NAFLD) and Non-alcoholic Steatohepatitis (NASH)
    Younossi ZM1, Loomba R2, Rinella ME3, Bugianesi E4, Marchesini G5, Neuschwander-Tetri BA6, Serfaty L7, Negro F8, Caldwell SH9, Ratziu V10, Corey KE11, Friedman SL12, Abdelmalek MF13, Harrison SA14, Sanyal AJ15, Lavine JE16, Mathurin P17, Charlton MR18, Chalasani NP19, Anstee QM20, Kowdley KV21, George J22, Goodman ZD1, Lindor K23. Hepatology. 2017 Dec 9. doi: 10.1002/hep.29724. [Epub ahead of print]


  290. Non-alcoholic fatty liver disease and lifestyle modifications, focusing on physical activity
    Kwak MS1, Kim D2. Korean J Intern Med. 2017 Dec 6. doi: 10.3904/kjim.2017.343. [Epub ahead of print]


  291. Association of Nonalcoholic Fatty Liver Disease With Lower Brain Volume in Healthy Middle-Aged Adults in the Framingham Study
    Weinstein G1, Zelber-Sagi S1,2, Preis SR3,4, Beiser AS3,4,5, DeCarli C6, Speliotes EK7,8, Satizabal CL4,5, Vasan RS4,5,9, Seshadri S4,5. JAMA Neurol. 2017 Nov 20. doi: 10.1001/jamaneurol.2017.3229. [Epub ahead of print]


  292. Cardiovascular Disease, Cancer, and Mortality Among People With Type 2 Diabetes and Alcoholic or Nonalcoholic Fatty Liver Disease Hospital Admission
    Wild SH, Walker JJ, Morling JR, McAllister DA, Colhoun HM, Farran B, McGurnaghan S, McCrimmon R, Read SH, Sattar N, Byrne CD; Scottish Diabetes Research Network Epidemiology Group. Diabetes Care. 2017 Nov 22. pii: dc171590. doi: 10.2337/dc17-1590. [Epub ahead of print]


  293. Role of imaging based biomarkers in NAFLD: Recent advances in clinical application and future research directions
    Loomba R1. J Hepatol. 2017 Dec 1. pii: S0168-8278(17)32472-8. doi: 10.1016/j.jhep.2017.11.028. [Epub ahead of print]


  294. Investigating Molecular Connections of Non-alcoholic Fatty Liver Disease with Associated Pathological Conditions in West Virginia for Biomarker Analysis
    Sharma DL1, Lakhani HV1, Klug RL2, Snoad B1, El-Hamdani R1, Shapiro JI1, Sodhi K2. J Clin Cell Immunol. 2017 Oct;8(5). pii: 523. doi: 10.4172/2155-9899.1000523. Epub 2017 Sep 29.


  295. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography
    Tsai E1, Lee TP2. Clin Liver Dis. 2018 Feb;22(1):73-92. doi: 10.1016/j.cld.2017.08.004.


  296. Clinical and Histologic Characterization of Nonalcoholic Steatohepatitis in African American Patients
    Bril F1,2, Portillo-Sanchez P1, Liu IC1, Kalavalapalli S1, Dayton K3, Cusi K4,2. Diabetes Care. 2017 Nov 13. pii: dc171349. doi: 10.2337/dc17-1349. [Epub ahead of print]


  297. Text messaging approach improves weight loss in patients with nonalcoholic fatty liver disease: A randomized study
    Axley P1, Kodali S2, Kuo YF3, Ravi S1, Seay T2, Parikh NM4, Singal AK2. Liver Int. 2017 Nov 8. doi: 10.1111/liv.13622. [Epub ahead of print]


  298. Pathophysiology of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis
    Manne V1, Handa P1, Kowdley KV2. Clin Liver Dis. 2018 Feb;22(1):23-37. doi: 10.1016/j.cld.2017.08.007. Epub 2017 Oct 18.


  299. Risk Factors for the Development of Nonalcoholic Fatty LiverDisease/Nonalcoholic Steatohepatitis, Including Genetics
    Lim HW1, Bernstein DE2. Clin Liver Dis. 2018 Feb;22(1):39-57. doi: 10.1016/j.cld.2017.08.008. Epub 2017 Oct 6.


  300. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Younossi ZM1, Henry L2, Bush H3, Mishra A4. Clin Liver Dis. 2018 Feb;22(1):1-10. doi: 10.1016/j.cld.2017.08.001. Epub 2017 Oct 14.


  301. Bariatric Surgery as an Efficient Treatment for Non-Alcoholic Fatty Liver Diseasein a Prospective Study with 1-Year Follow-up : BariScan Study
    Nickel F1, Tapking C1, Benner L2, Sollors J3, Billeter AT1, Kenngott HG1, Bokhary L1, Schmid M1, von Frankenberg M1, Fischer L1, Mueller S3, Müller-Stich BP4. Obes Surg. 2017 Nov 9. doi: 10.1007/s11695-017-3012-z. [Epub ahead of print]


  302. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis in Liver Transplantation
    Carter D1, Dieterich DT2, Chang C2. Clin Liver Dis. 2018 Feb;22(1):213-227. doi: 10.1016/j.cld.2017.08.015. Epub 2017 Oct 6.


  303. Hypertension, diabetes, atherosclerosis and NASH: Cause or consequence?
    Lonardo A1, Nascimbeni F1, Mantovani A2, Targher G3. J Hepatol. 2017 Nov 2. pii: S0168-8278(17)32335-8. doi: 10.1016/j.jhep.2017.09.021. [Epub ahead of print]


  304. Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration
    Patel YA1, Gifford EJ1, Glass LM2, McNeil R1, Turner MJ1, Han B1, Provenzale D1, Choi SS1, Moylan CA1, Hunt CM1. Aliment Pharmacol Ther. 2017 Nov 8. doi: 10.1111/apt.14411. [Epub ahead of print]


  305. Emerging Treatments for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Gawrieh S1, Chalasani N2. Clin Liver Dis. 2018 Feb;22(1):189-199. doi: 10.1016/j.cld.2017.08.013. Epub 2017 Oct 10.


  306. Non-alcoholic Fatty Liver Disease in Morbidly Obese Individuals Undergoing Bariatric Surgery: Prevalence and Effect of the Pre-Bariatric Very Low Calorie Diet
    Schwenger KJP1,2, Fischer SE2,3, Jackson TD4,5, Okrainec A1,4,5, Allard JP6,7,8. Obes Surg. 2017 Nov 2. doi: 10.1007/s11695-017-2980-3. [Epub ahead of print]


  307. Nonalcoholic Fatty Liver Disease and Metabolic Syndrome
    Kim D1, Touros A1, Kim WR2. Clin Liver Dis. 2018 Feb;22(1):133-140. doi: 10.1016/j.cld.2017.08.010. Epub 2017 Oct 21.


  308. Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma
    Massoud O1, Charlton M2. Clin Liver Dis. 2018 Feb;22(1):201-211. doi: 10.1016/j.cld.2017.08.014.


  309. Pharmacotherapy for NASH: Current and emerging
    Konerman MA1, Jones JC2, Harrison SA3. J Hepatol. 2017 Nov 6. pii: S0168-8278(17)32394-2. doi: 10.1016/j.jhep.2017.10.015. [Epub ahead of print]


  310. Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease
    Woodhouse CA1, Patel VC1, Singanayagam A1, Shawcross DL1. Aliment Pharmacol Ther. 2017 Oct 30. doi: 10.1111/apt.14397. [Epub ahead of print]


  311. Endocrine Disruptors and Developmental Origins of Nonalcoholic Fatty Liver Disease
    Treviño LS1, Katz TA1. Endocrinology. 2017 Nov 6. doi: 10.1210/en.2017-00887. [Epub ahead of print]


  312. Care standards for non-alcoholic fatty liver disease in the United Kingdom 2016: a cross-sectional survey
    Sheridan DA1, Aithal G2, Alazawi W3, Allison M4, Anstee Q5, Cobbold J6, Khan S7, Fowell A8, McPherson S9, Newsome PN10,11, Oben J12, Tomlinson J13, Tsochatzis E14. Frontline Gastroenterol. 2017 Oct;8(4):252-259. doi: 10.1136/flgastro-2017-100806. Epub 2017 Apr 28.


  313. The Natural History of Nonalcoholic Fatty Liver Disease-An Evolving View
    Lindenmeyer CC1, McCullough AJ2. Clin Liver Dis. 2018 Feb;22(1):11-21. doi: 10.1016/j.cld.2017.08.003.


  314. The Use of Liver Biopsy in Nonalcoholic Fatty Liver Disease: When to Biopsy and in Whom
    Gunn NT1, Shiffman ML2. Clin Liver Dis. 2018 Feb;22(1):109-119. doi: 10.1016/j.cld.2017.08.006.


  315. Steatosis and NASH in type 2 diabetes
    Hu M1, Phan F1, Bourron O2, Ferré P1, Foufelle F3. . Biochimie. 2017 Oct 31. pii: S0300-9084(17)30271-7. doi: 10.1016/j.biochi.2017.10.019. [Epub ahead of print]


  316. Nonalcoholic Steatohepatitis (NASH) and Hepatic Fibrosis: Emerging Therapies
    Wattacheril J1, Issa D2, Sanyal A2. Annu Rev Pharmacol Toxicol. 2017 Oct 20. doi: 10.1146/annurev-pharmtox-010617-052545. [Epub ahead of print]


  317. The Microbiome That Shapes Us: Can It Cause Obesity?
    Omer E1, Atassi H2. Curr Gastroenterol Rep. 2017 Oct 27;19(12):59. doi: 10.1007/s11894-017-0600-y.


  318. Adherence to Mediterranean Diet and Non-Alcoholic Fatty Liver Disease: Effect on Insulin Resistance
    Baratta F1,2, Pastori D1,2, Polimeni L1, Bucci T3, Ceci F4, Calabrese C1, Ernesti I5, Pannitteri G6, Violi F1, Angelico F7, Del Ben M1. Am J Gastroenterol. 2017 Oct 24. doi: 10.1038/ajg.2017.371. [Epub ahead of print]


  319. Updates on Dietary Models of Non-Alcoholic Fatty Liver Disease: Current Studies and Insights
    Stephenson K1, Kennedy L2, Hargrove L3, Demieville J2, Thomson J2, Alpini G2, Francis H2. Gene Expr. 2017 Nov 2. doi: 10.3727/105221617X15093707969658. [Epub ahead of print]


  320. Non-invasive diagnosis of non-alcoholic fatty liver disease (NAFLD) using ultrasound image echogenicity
    Benjamin A, Zubajlo R, Thomenius K, Dhyani M, Kaliannan K, Samir AE, Anthony BW. Conf Proc IEEE Eng Med Biol Soc. 2017 Jul;2017:2920-2923. doi: 10.1109/EMBC.2017.8037468.


  321. Impact of bariatric surgery on outcomes of patients with nonalcoholic fatty liverdisease: a nationwide inpatient sample analysis, 2004-2012
    McCarty TR1, Echouffo-Tcheugui JB2, Lange A1, Haque L1, Njei B3. Surg Obes Relat Dis. 2017 Sep 14. pii: S1550-7289(17)30919-X. doi: 10.1016/j.soard.2017.09.511. [Epub ahead of print]


  322. Benefit-risk of intraoperative liver biopsy during bariatric surgery: review and perspectives
    Barbois S1, Arvieux C2, Leroy V3, Reche F2, Stürm N4, Borel AL5. Surg Obes Relat Dis. 2017 Oct;13(10):1780-1786. doi: 10.1016/j.soard.2017.07.032. Epub 2017 Aug 14.


  323. Treatment Strategies for Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Golabi P1, Bush H1, Younossi ZM2. Clin Liver Dis. 2017 Nov;21(4):739-753. doi: 10.1016/j.cld.2017.06.010. Epub 2017 Jul 29.


  324. Diagnostic Accuracy of Magnetic Resonance Imaging Hepatic Proton Density Fat Fraction in Pediatric Nonalcoholic Fatty Liver Disease
    Middleton MS1, Van Natta ML2, Heba ER1, Alazraki A3, Trout AT4, Masand P5, Brunt EM6, Kleiner DE7, Doo E8, Tonascia J2, Lavine JE9, Shen W9, Hamilton G1, Schwimmer JB10, Sirlin CB1; NASH Clinical Research Network. Hepatology. 2017 Oct 13. doi: 10.1002/hep.29596. [Epub ahead of print]


  325. Challenges in Screening for Pediatric Nonalcoholic Fatty Liver Disease
    Ferguson AE1, Xanthakos SA1, Siegel RM1. Clin Pediatr (Phila). 2017 Oct 1:9922817733300. doi: 10.1177/0009922817733300. [Epub ahead of print]


  326. Noninvasive Testing for Nonalcoholic Steatohepatitis and Hepatic Fibrosis in Patients With Psoriasis Receiving Long-term Methotrexate Sodium Therapy
    Bauer B1, Chyou PH2, Stratman EJ3, Green C3. JAMA Dermatol. 2017 Aug 23. doi: 10.1001/jamadermatol.2017.2083. [Epub ahead of print]


  327. The Association of Inflammatory Markers With Nonalcoholic Fatty Liver Disease Differs by Human Immunodeficiency Virus Serostatus
    Price JC1, Wang R2, Seaberg EC2, Budoff MJ3, Kingsley LA4, Palella FJ5, Witt MD6, Post WS3, Thio CL7. Open Forum Infect Dis. 2017 Jul 23;4(3):ofx153. doi: 10.1093/ofid/ofx153. eCollection 2017 Summer.


  328. Developmental Programming of Obesity and Liver Metabolism by Maternal Perinatal Nutrition Involves the Melanocortin System
    Cordero P1, Li J2, Nguyen V3, Pombo J4, Maicas N5, Novelli M6, Taylor PD7, Samuelsson AM8, Vinciguerra M9,10, Oben JA11,12. Nutrients. 2017 Sep 20;9(9). pii: E1041. doi: 10.3390/nu9091041.


  329. Histopathology, grading and staging of nonalcoholic fatty liver disease
    Kleiner D1. Minerva Gastroenterol Dietol. 2017 Sep 25. doi: 10.23736/S1121-421X.17.02445-X. [Epub ahead of print]


  330. Performance of fibrosis prediction scores in paediatric non-alcoholic fatty liver disease
    Jackson JA1, Konomi JV2, Mendoza MV2, Krasinskas A3, Jin R2, Caltharp S3, Mouzaki M4, Vos MB2. J Paediatr Child Health. 2017 Sep 25. doi: 10.1111/jpc.13689. [Epub ahead of print]


  331. Coffee consumption is not associated with prevalent subclinical cardiovascular disease (CVD) or the risk of CVD events, in nonalcoholic fatty liver disease: results from the multi-ethnic study of atherosclerosis
    Simon TG1, Trejo MEP2, Zeb I3, Frazier-Wood AC4, McClelland RL2, Chung RT1, Budoff MJ5. Metabolism. 2017 Oct;75:1-5. doi: 10.1016/j.metabol.2017.06.007. Epub 2017 Jun 24.


  332. Isocaloric Dietary Changes and Non-Alcoholic Fatty Liver Disease in High Cardiometabolic Risk Individuals
    Della Pepa G1, Vetrani C2, Lombardi G3, Bozzetto L4, Annuzzi G5, Rivellese AA6. Nutrients. 2017 Sep 26;9(10). pii: E1065. doi: 10.3390/nu9101065.


  333. Rising Rates of Hepatocellular Carcinoma Leading to Liver Transplantation in Baby Boomer Generation with Chronic Hepatitis C, Alcohol Liver Disease, and Nonalcoholic Steatohepatitis-Related Liver Disease
    Cholankeril G1, Yoo ER2, Perumpail RB3, Liu A4, Sandhu JS5, Nair S6, Hu M7, Ahmed A8. Diseases. 2017 Sep 26;5(4). pii: E20. doi: 10.3390/diseases5040020.


  334. Bile acid alterations are associated with insulin resistance, but not with NASH in obese subjects
    Legry V1, Francque S2,3, Haas JT1, Verrijken A3,4, Caron S1, Chávez-Talavera O1, Vallez E1, Vonghia L2,3, Dirinck E4, Verhaegen A4, Kouach M5, Lestavel S1, Lefebvre P1, Van Gaal L3,4, Tailleux A1, Paumelle R1, Staels B1. J Clin Endocrinol Metab. 2017 Aug 4. doi: 10.1210/jc.2017-01397. [Epub ahead of print]


  335. Energy-matched moderate and high intensity exercise training improves nonalcoholic fatty liver disease risk independent of changes in body mass or abdominal adiposity - a randomized trial
    Winn NC1, Ying L1, Rector RS2, Parks EJ1, Ibdah JA3, Kanaley JA4. Metabolism. 2017 Sep 20. pii: S0026-0495(17)30228-7. doi: 10.1016/j.metabol.2017.08.012. [Epub ahead of print]


  336. Nonalcoholic Fatty Liver Disease Incidence and Impact on Metabolic Burden and Death: a 20 Year-Community Study
    Allen AM1, Terry TM2, Larson JJ2, Coward A1, Somers VK3, Kamath PS1. Hepatology. 2017 Sep 23. doi: 10.1002/hep.29546. [Epub ahead of print]


  337. Fatty liver without a large
    Yousef MH1, Al Juboori A1, Albarrak AA1, Ibdah JA1, Tahan V1. World J Gastrointest Pathophysiol. 2017 Aug 15;8(3):100-107. doi: 10.4291/wjgp.v8.i3.100.


  338. Nonalcoholic Fatty Liver Disease as a Nexus of Metabolic and Hepatic Diseases
    Samuel VT1, Shulman GI2. Cell Metab. 2017 Aug 29. pii: S1550-4131(17)30487-4. doi: 10.1016/j.cmet.2017.08.002. [Epub ahead of print]


  339. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention
    Younossi Z1,2, Anstee QM3,4, Marietti M5, Hardy T3,4, Henry L1,2, Eslam M6, George J6, Bugianesi E5. Nat Rev Gastroenterol Hepatol. 2017 Sep 20. doi: 10.1038/nrgastro.2017.109. [Epub ahead of print]


  340. Rising Rate of Liver Transplantation in the Baby Boomer Generation with Non-alcoholic Steatohepatitis in the United States
    Siddique O1, Joseph-Talreja M2, Yoo ER3, Perumpail RB2, Cholankeril G4, Harrison SA5, Younossi ZM6, Wong RJ7, Ahmed A2. J Clin Transl Hepatol. 2017 Sep 28;5(3):193-196. doi: 10.14218/JCTH.2017.00003. Epub 2017 Jun 3.


  341. Current Modalities of Fibrosis Assessment in Non-alcoholic Fatty Liver Disease
    Cheah MC1, McCullough AJ2,3, Goh GB1,4. J Clin Transl Hepatol. 2017 Sep 28;5(3):261-271. doi: 10.14218/JCTH.2017.00009. Epub 2017 Jun 24.


  342. Mediterranean Diet and Multi-Ingredient-Based Interventions for the Management of Non-Alcoholic Fatty Liver Disease
    Suárez M1, Boqué N2, Del Bas JM3, Mayneris-Perxachs J4, Arola L5,6, Caimari A7. Nutrients. 2017 Sep 22;9(10). pii: E1052. doi: 10.3390/nu9101052.


  343. Reversal of fibrosis in patients with nonalcoholic steatohepatosis after gastric bypass surgery
    Parker BM1,2, Wu J3, You J4, Barnes DS5, Yerian L6, Kirwan JP7, Schauer PR8, Sessler DI9. BMC Obes. 2017 Sep 12;4:32. doi: 10.1186/s40608-017-0168-y. eCollection 2017.


  344. Nuclear lamina genetic variants, including a truncated LAP2, in twins and siblings with nonalcoholic fatty liver disease
    Brady GF1, Kwan R1, Ulintz PJ2, Nguyen P3, Bassirian S3, Basrur V2, Nesvizhskii AI2,4, Loomba R3, Omary MB1. Hepatology. 2017 Sep 13. doi: 10.1002/hep.29522. [Epub ahead of print]


  345. Can Diet Help Non-Obese Individuals with Non-Alcoholic Fatty Liver Disease (NAFLD)?
    Merchant HA1. J Clin Med. 2017 Sep 19;6(9). pii: E88. doi: 10.3390/jcm6090088.


  346. The ASK1 Inhibitor Selonsertib in Patients with Nonalcoholic Steatohepatitis: A Randomized, Phase 2 Trial
    Loomba R1, Lawitz E2, Mantry PS3, Jayakumar S4, Caldwell SH5, Arnold H6, Diehl AM7, Djedjos CS8, Han L8, Myers RP8, Subramanian GM8, McHutchison JG8, Goodman ZD9, Afdhal NH10, Charlton MR11; GS-US-384-1497 Investigators. Hepatology. 2017 Sep 11. doi: 10.1002/hep.29514. [Epub ahead of print]


  347. Impact of body mass index in liver transplantation for nonalcoholic fatty liverdisease and alcoholic liver disease
    O'Neill S1, Napetti S1, Cornateanu S1, Sutherland AI1, Wigmore S1, Oniscu GC1, Adair A2. HPB (Oxford). 2017 Sep 7. pii: S1365-182X(17)30873-0. doi: 10.1016/j.hpb.2017.08.003. [Epub ahead of print]


  348. Methotrexate Hepatotoxicity and the Impact of Nonalcoholic Fatty Liver Disease
    Shetty A1, Cho W1, Alazawi W2, Syn WK3. Am J Med Sci. 2017 Aug;354(2):172-181. doi: 10.1016/j.amjms.2017.03.014. Epub 2017 Mar 14.


  349. Obstetric Outcomes in Women with Nonalcoholic Fatty Liver Disease
    Lee YW1, Yarrington CD2. Metab Syndr Relat Disord. 2017 Aug 28. doi: 10.1089/met.2017.0058. [Epub ahead of print]


  350. Alcohol and Obesity: A Dangerous Association for Fatty Liver Disease
    Mahli A1, Hellerbrand C. Dig Dis. 2016;34 Suppl 1:32-9. doi: 10.1159/000447279. Epub 2016 Aug 22.


  351. Discrimination of Nonalcoholic Steatohepatitis Using Transient Elastography in Patients with Nonalcoholic Fatty Liver Disease
    Lee HW1, Park SY2, Kim SU1, Jang JY3, Park H4, Kim JK1, Lee CK5, Chon YE1, Han KH1. PLoS One. 2016 Jun 10;11(6):e0157358. doi: 10.1371/journal.pone.0157358. eCollection 2016.


  352. Formulation for Effective Screening and Management of Nonalcoholic Steatohepatitis: Noninvasive NAFLD Management Strategy
    Hirose K1, Kanefuji T2, Suda T2, Sugitani S3, Nagasaki K4, Kubota T5, Igarashi M1, Terai S1. Gastroenterol Res Pract. 2016;2016:6343656. doi: 10.1155/2016/6343656. Epub 2016 Jun 13.


  353. The impact of body weight gain on nonalcoholic fatty liver disease and metabolic syndrome during earlier and later adulthood
    Du S1, Wang C2, Jiang W3, Li C4, Li Y1, Feng R5, Sun C6. Diabetes Res Clin Pract. 2016 Jun;116:183-91. doi: 10.1016/j.diabres.2016.04.047. Epub 2016 Apr 30.


  354. The Association between Non-Invasive Hepatic Fibrosis Markers and Cardiometabolic Risk Factors in the Framingham Heart Study
    Long MT1,2, Pedley A2,3, Massaro JM2,4, Hoffmann U5, Fox CS2,6. PLoS One. 2016 Jun 24;11(6):e0157517. doi: 10.1371/journal.pone.0157517. eCollection 2016.


  355. Nonalcoholic fatty liver disease and obstructive sleep apnea
    Aron-Wisnewsky J1, Clement K2, Pépin JL3. Metabolism. 2016 Aug;65(8):1124-35. doi: 10.1016/j.metabol.2016.05.004. Epub 2016 May 13.


  356. Host factors are dominant in the development of post-liver transplant non-alcoholic steatohepatitis
    Boga S1, Munoz-Abraham AS1, Rodriguez-Davalos MI1, Emre SH1, Jain D1, Schilsky ML1. World J Hepatol. 2016 May 28;8(15):659-64. doi: 10.4254/wjh.v8.i15.659.


  357. Non-alcoholic fatty liver disease and dyslipidemia: An update
    Katsiki N1, Mikhailidis DP2, Mantzoros CS3.Author information Metabolism. 2016 May 13. pii: S0026-0495(16)30018-X. doi: 10.1016/j.metabol.2016.05.003. [Epub ahead of print]


  358. The Natural Course of Non-Alcoholic Fatty Liver Disease
    Calzadilla Bertot L1, Adams LA2,3. Int J Mol Sci. 2016 May 20;17(5). pii: E774. doi: 10.3390/ijms17050774.


  359. Lifestyle and Dietary Interventions in the Management of Nonalcoholic Fatty Liver Disease
    Hannah WN Jr1, Harrison SA2. Dig Dis Sci. 2016 May;61(5):1365-74. doi: 10.1007/s10620-016-4153-y.


  360. Gut Microbiota and Lifestyle Interventions in NAFLD
    Houghton D1, Stewart CJ2, Day CP3,4, Trenell M5. Int J Mol Sci. 2016 Mar 25;17(4). pii: E447. doi: 10.3390/ijms17040447.


  361. A Comprehensive Updated Review of Pharmaceutical and Nonpharmaceutical Treatment for NAFLD
    Hossain N1, Kanwar P1, Mohanty SR1. Gastroenterol Res Pract. 2016;2016:7109270. doi: 10.1155/2016/7109270. Epub 2016 Feb 23.


  362. Fibrosis Assessment in Nonalcoholic Fatty Liver Disease (NAFLD) in 2016
    Kaswala DH1, Lai M1, Afdhal NH2. Dig Dis Sci. 2016 May;61(5):1356-64. doi: 10.1007/s10620-016-4079-4. Epub 2016 Mar 26.


  363. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection-Liver: The
    Ballestri S1, Nascimbeni F2,3, Romagnoli D4, Baldelli E5, Targher G6, Lonardo A7. Int J Mol Sci. 2016 Mar 9;17(3). pii: E355. doi: 10.3390/ijms17030355.


  364. Biopsy and Noninvasive Methods to Assess Progression of Nonalcoholic Fatty Liver Disease
    Bedossa P1, Patel K2. Gastroenterology. 2016 Mar 19. pii: S0016-5085(16)00354-1. doi: 10.1053/j.gastro.2016.03.008. [Epub ahead of print]


  365. Telomeres, NAFLD and Chronic Liver Disease
    Donati B1, Valenti L2. Int J Mol Sci. 2016 Mar 15;17(3). pii: E383. doi: 10.3390/ijms17030383.


  366. Non-alcoholic fatty liver disease and liver transplantation
    Khan RS1, Newsome PN2. Metabolism. 2016 Mar 3. pii: S0026-0495(16)00052-4. doi: 10.1016/j.metabol.2016.02.013. [Epub ahead of print]


  367. Perspectives on Treatment for Nonalcoholic Steatohepatitis
    Lassailly G1, Caiazzo R2, Pattou F2, Mathurin P3. Gastroenterology. 2016 Mar 10. pii: S0016-5085(16)00323-1. doi: 10.1053/j.gastro.2016.03.004. [Epub ahead of print]


  368. Comparison of Doppler ultrasound and transient elastography in the diagnosis of significant fibrosis in patients with nonalcoholic steatohepatitis
    Ergelen R1, Yilmaz Y2, Asedov R3, Celikel C4, Akin H2, Bugdayci O3, Altun E5, Tuney D3. Abdom Radiol (NY). 2016 Mar 10. [Epub ahead of print]


  369. Metabolic Impact of Nonalcoholic Steatohepatitis in Obese Patients With Type 2 Diabetes
    Lomonaco R1, Bril F2, Portillo-Sanchez P2, Ortiz-Lopez C3, Orsak B3, Biernacki D2, Lo M4, Suman A5, Weber MH6, Cusi K7. Diabetes Care. 2016 Feb 9. pii: dc151876. [Epub ahead of print]


  370. Cost-Effectiveness Analysis: Risk Stratification of Nonalcoholic Fatty Liver Disease (NAFLD) by the Primary Care Physician Using the NAFLD Fibrosis Score
    Tapper EB1, Hunink MG2,3, Afdhal NH1, Lai M1, Sengupta N4. PLoS One. 2016 Feb 23;11(2):e0147237. doi: 10.1371/journal.pone.0147237. eCollection 2016.


  371. Histamine H2-Receptor Antagonist Use Is Associated With Lower Prevalence of Nonalcoholic Fatty Liver Disease: A Population-based Study From the National Health and Nutrition Examination Survey, 2001-2006
    Shen H1, Liangpunsakul S. J Clin Gastroenterol. 2016 Feb 22. [Epub ahead of print]


  372. Steatohepatitis and liver fibrosis are predicted by the characteristics of very low density lipoprotein in nonalcoholic fatty liver disease
    Jiang ZG1, Tapper EB1, Connelly MA2, Pimentel CM1, Feldbrügge L1, Kim M3, Krawczyk S3, Afdh Al N1, Robson SC1, Herman M3, Otvos JD2, Mukamal KJ4, Lai M1. Liver Int. 2016 Jan 27. doi: 10.1111/liv.13076. [Epub ahead of print]


  373. Screening for Nonalcoholic Steatohepatitis in Individuals with Type 2 Diabetes: A Cost-Effectiveness Analysis
    Corey KE1,2, Klebanoff MJ3,4, Tramontano AC5, Chung RT6,7, Hur C8,9,10. Dig Dis Sci. 2016 Jan 29. [Epub ahead of print]


  374. Nonalcoholic Steatohepatitis: Diagnostic Challenges
    Gill RM1, Kakar S2. Surg Pathol Clin. 2013 Jun;6(2):227-57. doi: 10.1016/j.path.2013.03.002. Epub 2013 May 4.


  375. Is There Any Relation between the Degree of Fatty Liver Disease and Severity of Lower Urinary Tract Symptoms?
    Song YA1, Kwon SS2, Doo SW3, Kim JH4, Yang WJ3, Song YS3. Urology. 2015 Dec 9. pii: S0090-4295(15)01099-7. doi: 10.1016/j.urology.2015.11.030. [Epub ahead of print]


  376. Circulating microRNAs in nonalcoholic fatty liver disease
    DiStefano JK1, Gerhard GS2. Expert Rev Gastroenterol Hepatol. 2015 Nov 25. [Epub ahead of print]


  377. Clinical patterns of hepatocellular carcinoma (hcc) in non alcoholic fatty liver disease (NAFLD): A multicenter prospective study
    Piscaglia F1, Svegliati-Baroni G2, Barchetti A3, Pecorelli A1, Marinelli S1, Tiribelli C3,4, Bellentani S3; HCC-NAFLD Italian Study group. Hepatology. 2015 Nov 24. doi: 10.1002/hep.28368. [Epub ahead of print]


  378. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study
    Armstrong MJ1, Gaunt P2, Aithal GP3, Barton D4, Hull D4, Parker R1, Hazlehurst JM5, Guo K4; LEAN trial team, Abouda G6, Aldersley MA7, Stocken D8, Gough SC5, Tomlinson JW5, Brown RM9, Hübscher SG10, Newsome PN11. Lancet. 2015 Nov 19. pii: S0140-6736(15)00803-X. doi: 10.1016/S0140-6736(15)00803-X. [Epub ahead of print]


  379. Non-alcoholic fatty liver disease and risk of cardiovascular disease
    Lonardo A1, Sookoian S2, Pirola CJ3, Targher G4. Metabolism. 2015 Sep 25. pii: S0026-0495(15)00271-1. doi: 10.1016/j.metabol.2015.09.017. [Epub ahead of print]


  380. Dietary approach in the treatment of nonalcoholic fatty liver disease
    Ferolla SM1, Silva LC1, Ferrari Mde L1, da Cunha AS1, Martins Fdos S1, Couto CA1, Ferrari TC1. World J Hepatol. 2015 Oct 28;7(24):2522-34. doi: 10.4254/wjh.v7.i24.2522.


  381. The Prevalence of Non-Alcoholic Fatty Liver Disease in Children and Adolescents: A Systematic Review and Meta-Analysis
    Anderson EL1, Howe LD1, Jones HE2, Higgins JP3, Lawlor DA1, Fraser A1. PLoS One. 2015 Oct 29;10(10):e0140908. doi: 10.1371/journal.pone.0140908. eCollection 2015.


  382. Non-alcoholic Steatohepatitis is Associated with Increased Mortality in Obese Patients Undergoing Bariatric Surgery
    Goossens N1, Hoshida Y2, Song WM3, Jung M4, Morel P4, Nakagawa S5, Zhang B3, Frossard JL6, Spahr L6, Friedman SL5, Negro F7, Rubbia-Brandt L8, Giostra E6. Clin Gastroenterol Hepatol. 2015 Oct 19. pii: S1542-3565(15)01406-8. doi: 10.1016/j.cgh.2015.10.010. [Epub ahead of print]


  383. Nonalcoholic Steatohepatitis is the Most Rapidly Growing Indication for Simultaneous Liver Kidney Transplantation in the United States
    Singal AK1, Hasanin M, Kaif M, Wiesner R, Kuo YF. Transplantation. 2015 Oct 16. [Epub ahead of print]


  384. Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD
    Nobili V1, Alisi A2, Musso G3, Scorletti E4,5, Calder PC4,5, Byrne CD4,5. Crit Rev Clin Lab Sci. 2015 Oct 14:1-15. [Epub ahead of print]


  385. Systematic review of genetic association studies involving histologically confirmed non-alcoholic fatty liver disease
    Wood KL1, Miller MH2, Dillon JF2. BMJ Open Gastroenterol. 2015 Feb 17;2(1):e000019. doi: 10.1136/bmjgast-2014-000019. eCollection 2015.


  386. Sex-specific differences in hepatic fat oxidation and synthesis may explain the higher propensity for NAFLD in men
    Pramfalk C1, Pavlides M2,3, Banerjee R2, McNeil CA1, Neubauer S2, Karpe F1,4, Hodson L1. J Clin Endocrinol Metab. 2015 Sep 28:jc20152649. [Epub ahead of print]


  387. Hype or Reality: Should Patients with Metabolic Syndrome-related NAFLD be on the Hunter-Gatherer (Paleo) Diet to Decrease Morbidity?
    Tarantino G1, Citro V2, Finelli C3. J Gastrointestin Liver Dis. 2015 Sep;24(3):359-68. doi: 10.15403/jgld.2014.1121.243.gta.


  388. Nonalcoholic fatty liver disease: Current status and future directions
    Demir M1, Lang S1, Steffen HM1. J Dig Dis. 2015 Sep 25. doi: 10.1111/1751-2980.12291. [Epub ahead of print]


  389. Nonalcoholic Fatty Liver Disease and Fibrosis in Youth Taking Psychotropic Medications: Literature Review, Case Reports, and Management
    Gracious BL1,2, Bhatt R2,3, Potter C4. J Child Adolesc Psychopharmacol. 2015 Oct 8. [Epub ahead of print]


  390. Relevance of low testosterone to non-alcoholic fatty liver disease
    Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.


  391. The Gut Microbiota and Nonalcoholic Fatty Liver Disease
    Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.


  392. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
    Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.


  393. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
    Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.


  394. Relevance of low testosterone to non-alcoholic fatty liver disease
    Mody A1, White D2, Kanwal F3, Garcia JM4. Cardiovasc Endocrinol. 2015 Sep 1;4(3):83-89.


  395. The Gut Microbiota and Nonalcoholic Fatty Liver Disease
    Quigley EM1, Monsour HP1. Semin Liver Dis. 2015 Aug;35(3):262-9. doi: 10.1055/s-0035-1562946. Epub 2015 Sep 17.


  396. Systemic Complications of Nonalcoholic Fatty Liver Disease: When the Liver Is Not an Innocent Bystander
    Vanni E1, Marengo A1, Mezzabotta L1, Bugianesi E1. Semin Liver Dis. 2015 Aug;35(3):236-49. doi: 10.1055/s-0035-1562944. Epub 2015 Sep 17.


  397. Hepatic Injury in Nonalcoholic Steatohepatitis Contributes to Altered Intestinal Permeability
    Luther J1, Garber JJ1, Khalili H1, Dave M2, Bale SS3, Jindal R3, Motola DL1, Luther S1, Bohr S3, Jeoung SW1, Deshpande V1, Singh G4, Turner JR4, Yarmush ML3, Chung RT1, Patel SJ3. Cell Mol Gastroenterol Hepatol. 2015 Mar;1(2):222-232.


  398. The Prevalence and Presumed Etiology of Elevated Aminotransferase Levels in a Pacific Northwest Tribal Community
    Scott J, Kowdley KV, Ioannou GN, Krantz E, Lallemand O, Tsosie U, Buchwald D. J Health Care Poor Underserved. 2015;26(3):957-66. doi: 10.1353/hpu.2015.0091.


  399. Burden of nonalcoholic fatty liver disease and advanced fibrosis in a Texas Hispanic community cohort
    Pan JJ1, Fisher-Hoch SP1, Chen C1, Feldstein AE1, McCormick JB1, Rahbar MH1, Beretta L1, Fallon MB1. World J Hepatol. 2015 Jun 18;7(11):1586-94. doi: 10.4254/wjh.v7.i11.1586.


  400. Dysregulated Hepatic Methionine Metabolism Drives Homocysteine Elevation in Diet-Induced Nonalcoholic Fatty Liver Disease
    Pacana T1, Cazanave S1, Verdianelli A1, Patel V1, Min HK1, Mirshahi F1, Quinlivan E2, Sanyal AJ1. PLoS One. 2015 Aug 31;10(8):e0136822. doi: 10.1371/journal.pone.0136822. eCollection 2015.


  401. Cost-Effective Evaluation of Nonalcoholic Fatty Liver Disease With NAFLD Fibrosis Score and Vibration Controlled Transient Elastography
    Tapper EB1, Sengupta N1, Hunink MG2,3, Afdhal NH1, Lai M1. Am J Gastroenterol. 2015 Sep;110(9):1298-304. doi: 10.1038/ajg.2015.241. Epub 2015 Aug 25.


  402. Nonmedicinal interventions in nonalcoholic fatty liver disease
    Neuman MG, Nanau RM, Cohen LB. Can J Gastroenterol Hepatol. 2015 Jun-Jul;29(5):241-52.


  403. Non-alcoholic fatty liver disease following liver transplantation: a clinical review
    Merola J1, Liapakis A2, Mulligan DC1, Yoo PS1. Clin Transplant. 2015 Sep;29(9):728-37. doi: 10.1111/ctr.12585. Epub 2015 Aug 11.


  404. Vitamin E has a beneficial effect on nonalcoholic fatty liver disease: a meta-analysis of randomized controlled trials
    Sato K1, Gosho M2, Yamamoto T3, Kobayashi Y3, Ishii N3, Ohashi T3, Nakade Y3, Ito K3, Fukuzawa Y3, Yoneda M3. Nutrition. 2015 Jul-Aug;31(7-8):923-30. doi: 10.1016/j.nut.2014.11.018. Epub 2014 Dec 24.


  405. Noninvasive Assessment of Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
    Buzzetti E1, Lombardi R1, De Luca L1, Tsochatzis EA1. Int J Endocrinol. 2015;2015:343828. doi: 10.1155/2015/343828. Epub 2015 Apr 30.


  406. Bile Acid Signaling: Mechanism for Bariatric Surgery, Cure for NASH?
    Kohli R1, Myronovych A, Tan BK, Salazar-Gonzalez RM, Miles L, Zhang W, Oehrle M, Sandoval DA, Ryan KK, Seeley RJ, Setchell KD. Dig Dis. 2015;33(3):440-6. doi: 10.1159/000371699. Epub 2015 May 27.


  407. Trends in the Burden of Non-alcoholic Fatty Liver Disease in a US Cohort of Veterans
    Kanwal F1, Kramer JR2, Duan Z2, Yu X3, White D4, El-Serag HB5. Clin Gastroenterol Hepatol. 2015 Aug 17. pii: S1542-3565(15)01109-X. doi: 10.1016/j.cgh.2015.08.010. [Epub ahead of print]


  408. Hepatocellular Carcinoma in the Setting of Non-cirrhotic Nonalcoholic Fatty Liver Disease and the Metabolic Syndrome: US Experience.
    Perumpail RB1, Wong RJ, Ahmed A, Harrison SA.

    Dig Dis Sci. 2015 Aug 7. [Epub ahead of print]


  409. Weight Loss Through Lifestyle Modification Significantly Reduces Features of Nonalcoholic Steatohepatitis.
    Vilar-Gomez E1, Martinez-Perez Y2, Calzadilla-Bertot L2, Torres-Gonzalez A2, Gra-Oramas B3, Gonzalez-Fabian L3, Friedman SL4, Diago M5, Romero-Gomez M6.

    Gastroenterology. 2015 Aug;149(2):367-378.e5. doi: 10.1053/j.gastro.2015.04.005. Epub 2015 Apr 10.


  410. Association of Non-alcoholic Fatty Liver Disease (NAFLD) with Hepatocellular Carcinoma (HCC) in the United States from 2004-2009
    Younossi ZM1,2,3, Otgonsuren M3, Henry L1,3, Venkatesan C2, Mishra A1, Erario M2, Hunt S1. Hepatology. 2015 Aug 14. doi: 10.1002/hep.28123. [Epub ahead of print]


  411. NAFLD Review: Diagnosis, Treatment and Outcomes
    Ahmed A1, Wong RJ2, Harrison SA3. Clin Gastroenterol Hepatol. 2015 Jul 27. pii: S1542-3565(15)00988-X. doi: 10.1016/j.cgh.2015.07.029. [Epub ahead of print]
 
Slide Library
NASH Slides
   Released: 2016
Webcast
Get Ready for the Global Epidemic of NASH: Evolving Diagnosis and Treatment Strategies
66 slides
 
 
   Released: 2015
Webcast
Best of the Liver Summit: PBC, NAFLD/NASH and HCV
78 slides
 
 
   Released: 2015
Webcast
Hepatology Update: New Developments in PBC, NAFLD & NASH
77 slides
 
 
   Released: 2015
Webcast
THE LIVER SUMMIT
89 slides
 
 
 
 
                               
 
HBV
Webcasts
Slide Library
Abstract Library
 
HCC
Slide Library
Abstract Library
 
 
HCV
Webcasts
Slide Library
Abstract Library
 
 
HE
Webcasts
Slide Library
Abstract Library
 
NASH
Webcasts
Slide Library
Abstract Library
 
 
PBC
Webcasts
Slide Library
Abstract Library
 
 
OTHER
Webcasts
Slide Library
   
   
 
About CLDF
Mission Statement
Board of Trustees
Board of Advisors/Faculty
CLDF Sponsors & Supporters
 
Other Resources
Liver News Library
Journal Abstracts
Hep C Link to Care
 
Centers of
Educational Expertise
Hepatology
Substance Use Disorder
             
CLDF Follow Us
   
  The Chronic Liver Disease Foundation is a non-profit organization with content developed specifically for healthcare professionals.
© Copyright 2012-2019 Chronic Liver Disease Foundation. All rights reserved. This site is maintained as an educational resource for US healthcare providers only.
Use of this Web site is governed by the Chronic Liver Disease Foundation terms of use and privacy statement.